Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 276. Отображено 101.
22-09-2006 дата публикации

Tamper-resistant oral opioid agonist formulations.

Номер: AP0000001665A
Автор: OSHLACK BENJAMIN [US], WRIGHT CURTIS [US], HADDOX DAVID J [US], OSHLACK BENJAMIN, WRIGHT CURTIS, HADDOX DAVID J, OSHLACK Benjamin, WRIGHT Curtis, HADDOX David J.
Принадлежит:

Disclosed is an oral dosage form comprising (i) an opioid agonists in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the amount of antagonist released from said dosage form after tampering to the amount of said antagonist released from said intact dosage form is about 4:1 or greater, based on the in-vitro dissolution at 1 hour of said dosage form in 900ml of Simulated Gastric Fluid using a USP Type II (paddle) apparatus at 75 rpm at 37 degrees C wherein said agonist and antagonist are interdispersed and are not isolated from each other in two distinct layers.

Подробнее
Номер записи: 1
05-01-2012 дата публикации

Nutraceutical Product Containing Anatabine And Yerba Maté

Номер: US20120003341A1
Автор: Williams Jonnie R., WRIGHT Curtis
Принадлежит: Rock Creek Pharmaceuticals, Inc.

Nutraceutical compositions containing anatabine and Yerba maté extract are efficacious for temporarily reducing the desire to smoke, reducing nicotine cravings, the treatment of smoking cessation, tobacco withdrawal symptoms, tobacco dependence, weight loss, and/or related disorders. 1. A composition comprising anatabine , a Yerba maté extract , and a pharmaceutically acceptable vehicle , diluent , or carrier.2. The composition of claim 1 , wherein the anatabine is synthetic anatabine.3. The composition of wherein anatabine is provided in the form of an extract of a plant selected from the group consisting of datura claim 1 , mandrake claim 1 , belladonna claim 1 , capsicum claim 1 , potato claim 1 , nicotiana claim 1 , eggplant claim 1 , and petunia.4. A method of providing an alternative to cigarette smoking that reduces the desire to smoke comprising administering to a subject in need thereof the composition of .5. The method of wherein the subject is a human.6. A method of treating at least one of smoking cessation claim 1 , tobacco withdrawal symptoms claim 1 , tobacco dependence claim 1 , and weight loss in a subject comprising administering to a subject in need thereof the composition of .7. The method of wherein the subject is a human.8. A nutraceutical composition comprising anatabine in an amount of from about 0.1 to about 0.5 mg claim 6 , Yerba maté extract in an amount of from about 1 to about 100 mg claim 6 , and a pharmaceutically acceptable vehicle claim 6 , diluent claim 6 , or carrier.9. The nutraceutical composition of claim 8 , wherein anatabine is present in an amount of from about 0.1 to about 0.3 mg.10. The nutraceutical composition of claim 8 , wherein anatabine is present in an amount of or from about 0.1 to about 0.2 mg.11. The nutraceutical composition of claim 8 , wherein the Yerba maté extract is present in an amount of from about 1 to about 50 mg.12. The nutraceutical composition of claim 11 , wherein the Yerba maté extract is present in ...

Подробнее
Номер записи: 2
03-05-2012 дата публикации

Pharmaceutical formulation containing gelling agent

Номер: US20120108622A1
Автор: Benjamin Oshlack, Christopher Breder, Curtis Wright
Принадлежит: Purdue Pharma LP

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Подробнее
Номер записи: 3
15-11-2012 дата публикации

Opioid Agonist Formulations with Releasable And Sequestered Antagonist

Номер: US20120288567A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит: Purdue Pharma L.P.

Disclosed are oral dosage forms, comprising (i) a therapeutically effective amount of an opioid agonist; (ii) an opioid antagonist in releasable form; and (iii) a sequestered opioid antagonist which is not released when the dosage form is administered intact, and methods thereof.

Подробнее
Номер записи: 4
22-08-2013 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20130217716A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 170-. (canceled)71. An extended release abuse deterrent dosage form comprising: (a) PEO having a molecular weight of from about 300,000 to about 5,000,000;', '(b) magnesium stearate; and', '(c) oxycodone or a pharmaceutically acceptable salt thereof;, 'a. a core matrix comprising a blended mixture ofwherein the matrix is heated to melt at least a portion of the PEO included in the matrix; andb. PEG applied onto the core matrix;wherein the dosage form provides extended release of the drug. This application is a continuation of U.S. patent application Ser. No. 13/349,449, filed Jan. 12, 2012, which is a continuation of U.S. patent application Ser. No. 12/653,115, filed Dec. 8, 2009, which is a continuation of U.S. patent application Ser. No. 10/214,412, filed Aug. 6, 2002, which claims the benefit of U.S. Provisional Application No. 60/310,534, filed Aug. 6, 2001. The contents of these applications are hereby incorporated by reference in their entirety.Opioid analgesics are sometimes the subject of abuse. Typically, a particular dose of an opioid analgesic is more potent when administered parenterally as compared to the same dose administered orally. Therefore, one popular mode of abuse of oral opioid formulations involves the extraction of the opioid from the dosage form, and the subsequent injection of the ...

Подробнее
Номер записи: 5
19-09-2013 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20130245055A1
Автор: Benjamin Oshlack, Christopher Breder, Curtis Wright
Принадлежит: PF Laboratories Inc, Purdue Pharmaceuticals LP

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Подробнее
Номер записи: 6
26-09-2013 дата публикации

TAMPER-RESISTANT ORAL OPIOID AGONIST FORMULATIONS

Номер: US20130251789A1
Автор: HADDOX J. David, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит: Purdue Pharma L.P.

Disclosed is an oral dosage form comprising: (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is not released when the dosage form is administered orally intact. 161-. (canceled)62. An oral dosage form comprising:(i) an opioid agonist and(ii) multiparticulates comprising an opioid antagonist in a substantially non-releasable form, which, when administered intact, release at least 0.025 mg, but less than 0.25 mg, of the opioid antagonist at 1 hour, and, when administered after tampering, 0.25 mg or more of the opioid antagonist at 1 hour, based on an in-vitro dissolution in 900 ml of Simulated Gastric Fluid using a USP Type II (paddle) apparatus at 75 rpm at 37° C.,wherein the opioid antagonist is naltrexone or a pharmaceutically acceptable salt thereof, and the opioid agonist is coated on the surface of the multiparticulates, or the mulitiparticulates and the opioid agonist are included in the dosage form as separate pellets.63. The dosage form of claim 62 , wherein the substantially non-releasable form comprises multiparticulates of the opioid antagonist individually coated with a material which substantially prevents the release of the opioid antagonist from the multiparticulates which are administered intact.64. The dosage form of claim 62 , wherein the substantially non-releasable form comprises multiparticulates comprising the opioid antagonist dispersed in a matrix comprising a material which substantially prevents the release of the opioid antagonist from the multiparticulates which are administered intact.65. The dosage form of claim 64 , wherein the material comprises an acrylic polymer.66. The dosage form of claim 62 , wherein the substantially non-releasable form comprises multiparticulates comprising inert beads coated with the opioid antagonist and overcoated with a material which substantially prevents the release of the opioid antagonist from the multiparticulates which are administered intact.67. The dosage form ...

Подробнее
Номер записи: 7
26-09-2013 дата публикации

SEQUESTERED ANTAGONIST FORMULATIONS

Номер: US20130251812A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит: Purdue Pharma L.P.

Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the mean Cmax of the antagonist after single dose oral administration of the dosage form after tampering to the mean Cmax of antagonist after single dose oral administration of an intact dosage form is at least 1.5:1. 1159-. (canceled)160. An oral dosage form consisting ofan opioid agonist,an opioid antagonist,one or more hydrophobic materials, andadditional pharmaceutically acceptable excipients, whereinthe opioid antagonist is naltrexone or a pharmaceutically acceptable salt and is sequestered with the one or more hydrophobic materials such that the opioid antagonist is substantially not released when the dosage form is administered intact but is released in an effective amount to eliminate the euphoric effect of the opioid agonist when the dosage form is tampered with, andthe dosage form which is administered intact provides a mean Cmax of naltrexone of 30 pg/ml or less, based on oral administration of the dosage form containing 1 mg of naltrexone hydrochloride or an equivalent amount of naltrexone base or a pharmaceutically acceptable salt thereof other than the hydrochloride salt.161. The dosage form of claim 160 , wherein the mean Cmax of naltrexone is 15 pg/ml or less.162. The dosage form of claim 161 , wherein the mean Cmax of naltrexone is 10 pg/ml or less.163. The dosage form of claim 162 , wherein the mean Cmax of naltrexone is 6 pg/ml or less.164. The dosage form of claim 163 , wherein the mean Cmax of naltrexone is 3 pg/ml or less.165. The dosage form of claim 164 , wherein the Cmax of naltrexone is 1 pg/ml.166. The dosage form of claim 160 , wherein the opioid agonist is selected from the group consisting of morphine claim 160 , hydromorphone claim 160 , hydrocodone claim 160 , oxycodone claim 160 , codeine claim 160 , ...

Подробнее
Номер записи: 8
03-10-2013 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20130261143A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 1. A controlled release oral dosage form comprising: a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; said dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; said dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.2. The controlled release oral dosage form of claim 1 , wherein said excipient comprises a controlled release material.3. The controlled release oral dosage form of claim 1 , wherein said gelling agent comprises a controlled release material.4. The controlled release oral dosage form of claim 1 , wherein said drug is an opioid analgesic selected from the group consisting of levorphanol claim 1 , meperidine claim 1 , dihydrocodeine claim 1 , dihydromorphine claim 1 , oxymorphone claim 1 , pharmaceutically acceptable salts thereof claim 1 , and mixtures thereof.5. The controlled release oral dosage form of claim 1 , wherein said drug is an opioid analgesic.6. The controlled release oral ...

Подробнее
Номер записи: 9
03-10-2013 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20130261144A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A controlled release oral dosage form comprising:from about 2.5 mg to about 800 mg morphine or a pharmaceutically acceptable salt thereof; anda gelling agent comprising polyethylene oxide in an effective amount to impart a viscosity of at least about 10 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid;the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.42. The controlled release oral dosage form of claim 41 , wherein the ratio of polyethylene oxide to morphine or pharmaceutically acceptable salt thereof is from about 1:40 to about 40:1.43. The controlled release oral dosage form of claim 41 , wherein the ratio of polyethylene oxide to morphine or pharmaceutically acceptable salt thereof is from about 1:1 to about 30:1.44. The controlled release oral dosage form of claim 41 , wherein the ratio of polyethylene oxide to morphine or pharmaceutically acceptable salt thereof is from about 2:1 to about 10:1.45. The controlled release oral dosage form of claim 41 , wherein the aqueous liquid is water.46. The controlled release oral dosage form of claim 41 , wherein the viscosity is imparted when the dosage form is subjected to tampering by dissolution in about 1 to ...

Подробнее
Номер записи: 10
03-10-2013 дата публикации

PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT

Номер: US20130261145A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A controlled release oral dosage form comprising:hydrocodone or a pharmaceutically acceptable salt thereof; anda gelling agent comprising polyethylene oxide in an effective amount to impart a viscosity of at least about 10 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid;the dosage form providing a therapeutic effect for at least about 24 hours when orally administered to a human patient.42. The controlled release oral dosage form of claim 41 , wherein the ratio of polyethylene oxide to hydrocodone or pharmaceutically acceptable salt thereof is from about 1:40 to about 40:1.43. The controlled release oral dosage form of claim 41 , wherein the ratio of polyethylene oxide to hydrocodone or pharmaceutically acceptable salt thereof is from about 1:1 to about 30:1.44. The controlled release oral dosage form of claim 41 , wherein the ratio of polyethylene oxide to hydrocodone or pharmaceutically acceptable salt thereof is from about 2:1 to about 10:1.45. The controlled release oral dosage form of claim 41 , wherein the aqueous liquid is water.46. The controlled release oral dosage form of claim 41 , wherein the viscosity is imparted when the dosage form is subjected to tampering by dissolution in about 1 to about 3 ml of aqueous ...

Подробнее
Номер записи: 11
14-11-2013 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20130303494A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 1. An immediate release oral dosage form comprising:a therapeutically effective amount of a drug susceptible to abuse;a gelling agent comprising xanthan gum in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is subject to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquidthe dosage form providing an immediate release of the drug when orally administered to a human patient.23-. (canceled)4. The immediate release oral dosage form of claim 1 , wherein the drug is an opioid analgesic selected from the group consisting of levorphanol claim 1 , meperidine claim 1 , dihydrocodeine claim 1 , dihydromorphine claim 1 , oxymorphone claim 1 , pharmaceutically acceptable salts thereof claim 1 , and mixtures thereof.5. The immediate release oral dosage form of claim 1 , wherein the drug is an opioid analgesic.6. The immediate release oral dosage form of claim 5 , wherein the opioid analgesic is morphine or a pharmaceutically acceptable salt thereof.7. The immediate release oral dosage form of claim 5 , wherein the opioid analgesic is hydromorphone or a pharmaceutically acceptable salt thereof.8. The immediate release oral dosage form of claim 5 , ...

Подробнее
Номер записи: 12
21-11-2013 дата публикации

Opiod Agonist Formulations with Releasable And Sequestered Antagonist

Номер: US20130309303A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит: Purdue Pharma L.P.

Disclosed are oral dosage forms, comprising (i) a therapeutically effective amount of an opioid agonist; (ii) an opioid antagonist in releasable form; and (iii) a sequestered opioid antagonist which is not released when the dosage form is administered intact, and methods thereof. 153-. (canceled)54. An oral dosage form comprising:(i) a therapeutically effective amount of an opioid agonist;(ii) an opioid antagonist in a releasable form; and(iii) an additional opioid antagonist combined with one or more pharmaceutically acceptable hydrophobic materials such that the additional opioid antagonist is substantially not released from the dosage form which is administered orally intact,wherein the opioid antagonist in the releasable form is naloxone or a pharmaceutically acceptable salt thereof, and at least one of the hydrophobic materials comprises a cellulose polymer or an acrylic polymer.55. An oral dosage form comprising:(i) a first component comprising a therapeutically effective amount of an opioid agonist, and an opioid antagonist in a releasable form comprising naloxone or a pharmaceutically acceptable salt thereof; and(ii) a second component comprising an additional opioid antagonist combined with one or more pharmaceutically acceptable hydrophobic materials such that the additional opioid antagonist is substantially not released from the dosage form which is administered orally intact, wherein at least one of the hydrophobic materials comprises a cellulose polymer or an acrylic polymer.56. The dosage form of claim 54 , further comprising a sustained release excipient which provides a sustained release of the opioid agonist and the opioid antagonist in the releasable form.57. The dosage form of claim 54 , wherein the additional opioid antagonist is in the form of multiparticulates individually coated with said one or more pharmaceutically acceptable hydrophobic materials.58. The dosage form of claim 54 , wherein the additional opioid antagonist is dispersed in a ...

Подробнее
Номер записи: 13
28-11-2013 дата публикации

PHARMACEUTICAL FORMULATION CONTAINING OPIOID AGONIST, OPIOID ANTAGONIST AND GELLING AGENT

Номер: US20130317051A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic, an opioid antagonist and one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid. 132-. (canceled)33. An oral dosage form comprising:(a) an analgesically effective amount of an opioid agonist,(b) an opioid antagonist in an effective amount to attenuate a side effect of the opioid agonist, and(c) a gelling agent selected from the group consisting of polyethylene oxides, surfactants, emulsifiers and mixtures thereof,wherein a weight ratio of the gelling agent to the opioid agonist is from about 1:40 to about 40:1, andthe gelling agent is in an effective amount to form a gel having a viscosity of at least about 10 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid.34. The oral dosage form of claim 33 , wherein the opioid agonist is selected from the group consisting of oxycodone claim 33 , codeine claim 33 , hydrocodone claim 33 , hydromorphone claim 33 , levorphanol claim 33 , meperidine claim 33 , morphine claim 33 , pharmaceutically acceptable salts thereof claim 33 , and mixtures thereof.35. The oral dosage form of claim 33 , wherein the opioid antagonist is naloxone or a pharmaceutically acceptable salt thereof.36. The oral dosage form of claim 33 , wherein the opioid antagonist is in a substantially non-releasable form and does not substantially block the analgesic effect of the opioid agonist when the dosage form is orally administered intact.37. The oral dosage form of claim 33 , wherein a weight ratio of the opioid agonist and the opioid antagonist is ...

Подробнее
Номер записи: 14
10-04-2014 дата публикации

TAMPER-RESISTANT ORAL OPIOID AGONIST FORMULATIONS

Номер: US20140099369A1
Автор: Haddox J.David, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит: Purdue Pharma L.P.

Disclosed is an oral dosage form comprising: (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is not released when the dosage form is administered orally intact. 161-. (canceled)62. A substantially non-releasable form of an opioid antagonist comprising:the opioid antagonist combined with one or more pharmaceutically acceptable hydrophobic material(s) such that the antagonist is not released or substantially not released during its transit through the gastrointestinal tract when administered orally in an intact oral dosage form, the intact dosage form comprising an opioid agonist, and less than 1% by weight of the opioid antagonist is released after 36 hours from the intact dosage form.63. The substantially non-releasable form of claim 62 , wherein the opioid antagonist is naltrexone or a pharmaceutically acceptable salt thereof.64. The substantially non-releasable form of claim 63 , which is adapted to release less than 0.5% by weight of the opioid antagonist from the intact oral dosage form after 36 hours.65. The substantially non-releasable form of claim 62 , which becomes bioavailable if subjected to crushing claim 62 , shearing claim 62 , grinding claim 62 , chewing claim 62 , dissolution in a solvent claim 62 , temperatures of greater than 45° C. claim 62 , or any combination thereof.66. The substantially non-releasable form of claim 63 , which is adapted to release less than 0.25 mg of naltrexone from the dosage form which is administered orally intact and 0.25 mg or more of naltrexone from the dosage form which is subjected to crushing claim 63 , shearing claim 63 , grinding claim 63 , chewing claim 63 , dissolution in a solvent claim 63 , temperatures of greater than 45° C. claim 63 , or any combination thereof claim 63 , the release based on the dissolution at 1 hour of the dosage form in 900 ml of Simulated Gastric Fluid using a USP Type II (paddle) apparatus at 75 rpm at 37° C.67. The substantially non-releasable ...

Подробнее
Номер записи: 15
10-04-2014 дата публикации

SEQUESTERED ANTAGONIST FORMULATIONS

Номер: US20140099376A2
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the mean Cmax of the antagonist after single dose oral administration of the dosage form after tampering to the mean Cmax of antagonist after single dose oral administration of an intact dosage form is at least 1.5:1. 160. An oral dosage form consisting ofan opioid agonist,an opioid antagonist,one or more hydrophobic materials, andadditional pharmaceutically acceptable excipients, whereinthe opioid antagonist is naltrexone or a pharmaceutically acceptable salt, andall of the opioid antagonist in the dosage form is sequestered with the one or more hydrophobic materials such that the opioid antagonist is substantially not released when the dosage form is administered intact but is released in an effective amount to eliminate the euphoric effect of the opioid agonist when the dosage form is tampered with, andthe dosage form which is administered intact provides a mean Cmax of naltrexone of 30 pg/ml or less, based on oral administration of the dosage form containing 1 mg of naltrexone hydrochloride or an equivalent amount of naltrexone base or a pharmaceutically acceptable salt thereof other than the hydrochloride salt.161. The dosage form of claim 160 , wherein the mean Cmax of naltrexone is 15 pg/ml or less.162. The dosage form of claim 161 , wherein the mean Cmax of naltrexone is 10 pg/ml or less.163. The dosage form of claim 162 , wherein the mean Cmax of naltrexone is 6 pg/ml or less.164. The dosage form of claim 163 , wherein the mean Cmax of naltrexone is 3 pg/ml or less.165. The dosage form of claim 164 , wherein the Cmax of naltrexone is 1 pg/ml.166. The dosage form of claim 160 , wherein the opioid agonist is selected from the group consisting of morphine claim 160 , hydromorphone claim 160 , hydrocodone claim 160 , oxycodone claim ...

Подробнее
Номер записи: 16
07-01-2016 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20160000712A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A controlled release oral solid dosage form comprising:(i) particles comprising methylphenidate or a pharmaceutically acceptable salt thereof and(ii) particles comprising polyethylene oxide,the dosage form providing a therapeutic effect for about 12 hours to about 24 hours when orally administered to a human patient, and when dissolved in from about 0.5 ml to about 10 ml of an aqueous liquid, forming a viscous gel,wherein the particles comprising polyethylene oxide are free from said methylphenidate or pharmaceutically acceptable salt thereof.42. The controlled release oral solid dosage form of claim 41 , wherein the viscous gel is unsuitable for injection.43. The controlled release oral solid dosage form of claim 41 , wherein the particles comprising polyethylene oxide comprise a hydrophobic material.44. The controlled release oral solid dosage form of claim 43 , wherein the hydrophobic material is an ammonio methacrylate copolymer.45. The controlled release oral solid dosage form of claim 41 , wherein the viscous gel cannot be injected through an insulin syringe.46. The controlled release oral solid dosage form of claim 41 , wherein the particles comprising polyethylene oxide comprise polyvinylpyrrolidone.47. The controlled release oral solid dosage form of claim 44 , wherein the particles ...

Подробнее
Номер записи: 17
07-01-2016 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20160000717A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A controlled release oral dosage form comprising:a matrix comprising a mixture of (i) hydrocodone or a pharmaceutically acceptable salt thereof;(ii) polyethylene oxide; and(iii) polyethylene glycol;the matrix imparting a viscosity unsuitable for parenteral administration when the dosage form is subjected to tampering by dissolution in from about 0.5 ml to about 10 ml of an aqueous liquid;the matrix having a ratio of polyethylene oxide to hydrocodone or pharmaceutically acceptable salt thereof from about 1:1 to about 1:40; andthe matrix providing a therapeutic effect for at least about 24 hours when orally administered to a human patient.42. The controlled release oral dosage form of claim 41 , further comprising a cellulosic polymer.43. The controlled release oral dosage form of claim 42 , wherein the cellulosic polymer is selected from the group consisting of microcrystalline cellulose claim 42 , hydroxyethylcellulose claim 42 , hydroxypropylcellulose claim 42 , and hydroxypropylmethylcellulose44. The controlled release oral dosage form of claim 43 , wherein the cellulosic polymer comprises microcrystalline cellulose.45. The controlled release oral dosage form of claim 43 , wherein the cellulosic polymer comprises hydroxypropylcellulose.46. The controlled release oral dosage form of claim 43 ...

Подробнее
Номер записи: 18
07-01-2016 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20160000718A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A controlled release oral dosage form comprising:a matrix comprising a mixture of (i) hydrocodone or a pharmaceutically acceptable salt thereof; and(ii) a gelling agent comprising polyethylene oxide and a cellulosic polymer, the gelling agent in an effective amount to impart a viscosity unsuitable for parenteral administration when the dosage form is subjected to tampering by dissolution in from about 0.5 ml to about 10 ml of an aqueous liquid;the matrix having a ratio of gelling agent to hydrocodone or pharmaceutically acceptable salt thereof from about 40:1 to about 1:40; andthe matrix providing a therapeutic effect for at least about 24 hours when orally administered to a human patient.42. The controlled release oral dosage form of claim 41 , wherein the cellulosic polymer is selected from the group consisting of microcrystalline cellulose claim 41 , sodium carboxymethylcellulose claim 41 , methylcellulose claim 41 , ethylcellulose claim 41 , hydroxyethylcellulose claim 41 , hydroxypropylcellulose claim 41 , and hydroxypropylmethylcellulose.43. The controlled release oral dosage form of claim 42 , wherein the cellulosic polymer comprises microcrystalline cellulose.44. The controlled release oral dosage form of claim 42 , wherein the cellulosic polymer comprises hydroxypropylcellulose.45. ...

Подробнее
Номер записи: 19
07-01-2016 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20160000719A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A controlled release oral dosage form comprising:a matrix comprising a mixture of (i) hydrocodone or a pharmaceutically acceptable salt thereof;(ii) polyethylene oxide; and(iii) a cellulosic polymer;the matrix imparting a viscosity unsuitable for parenteral administration when the dosage form is subjected to tampering by dissolution in from about 0.5 ml to about 10 ml of an aqueous liquid;the matrix having a ratio of polyethylene oxide to hydrocodone or pharmaceutically acceptable salt thereof from about 40:1 to about 1:40;the matrix providing a therapeutic effect for at least about 24 hours when orally administered to a human patient.42. The controlled release oral dosage form of claim 41 , wherein the cellulosic polymer is selected from the group consisting of microcrystalline cellulose claim 41 , hydroxyethylcellulose claim 41 , hydroxypropylcellulose claim 41 , and hydroxypropylmethylcellulose.43. The controlled release oral dosage form of claim 42 , wherein the cellulosic polymer comprises microcrystalline cellulose.44. The controlled release oral dosage form of claim 42 , wherein the cellulosic polymer comprises hydroxypropylcellulose.45. The controlled release oral dosage form of claim 42 , wherein the cellulosic polymer comprises hydroxypropylcellulose and microcrystalline cellulose. ...

Подробнее
Номер записи: 20
07-01-2016 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20160000723A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A controlled release oral solid dosage form comprising:(i) particles comprising hydrocodone bitartrate and(ii) particles comprising polyethylene oxide,the dosage form providing a therapeutic effect for about 12 hours to about 24 hours when orally administered to a human patient, and when dissolved in from about 0.5 ml to about 10 ml of an aqueous liquid, forming a viscous gel,wherein the particles comprising polyethylene oxide are free from hydrocodone bitartrate, and hydrocodone bitartrate is the only drug in the dosage form.42. The controlled release oral solid dosage form of claim 41 , wherein the viscous gel is unsuitable for injection.43. The controlled release oral solid dosage form of claim 41 , wherein the particles comprising polyethylene oxide comprise a hydrophobic material.44. The controlled release oral solid dosage form of claim 43 , wherein the hydrophobic material is an ammonio methacrylate copolymer.45. The controlled release oral solid dosage form of claim 41 , wherein the viscous gel cannot be injected through an insulin syringe.46. The controlled release oral solid dosage form of claim 41 , wherein the particles comprising polyethylene oxide comprise polyvinylpyrrolidone.47. The controlled release oral solid dosage form of claim 44 , wherein the particles comprising ...

Подробнее
Номер записи: 21
07-01-2016 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20160000776A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A controlled release oral dosage form comprising:a matrix comprising a mixture of (i) hydrocodone or a pharmaceutically acceptable salt thereof; and(ii) a gelling agent comprising polyethylene oxide and polyethylene glycol, the gelling agent in an effective amount to impart a viscosity unsuitable for parenteral administration when the dosage form is subjected to tampering by dissolution in from about 0.5 ml to about 10 ml of an aqueous liquid;the matrix having a ratio of gelling agent to hydrocodone or pharmaceutically acceptable salt thereof from about 1:1 to about 1:40; andthe matrix providing a therapeutic effect for at least about 24 hours when orally administered to a human patient.42. The controlled release oral dosage form of claim 41 , wherein the gelling agent further comprises a cellulosic polymer.43. The controlled release oral dosage form of claim 42 , wherein the cellulosic polymer is selected from the group consisting of microcrystalline cellulose claim 42 , sodium carboxymethylcellulose claim 42 , methylcellulose claim 42 , ethylcellulose claim 42 , hydroxyethylcellulose claim 42 , hydroxypropylcellulose claim 42 , and hydroxypropylmethylcellulose44. The controlled release oral dosage form of claim 43 , wherein the cellulosic polymer comprises microcrystalline cellulose.45. The ...

Подробнее
Номер записи: 22
01-01-2015 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20150005331A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A pharmaceutical dosage form comprising:a mixture comprising (i) buprenorphine or a pharmaceutically acceptable salt thereof; and(ii) a gelling agent comprising polyethylene oxide, the gelling agent in an effective amount to impart a viscosity of at least about 10 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid;the dosage form providing an immediate release upon administration to a human patient.42. The pharmaceutical dosage form of claim 41 , further comprising buprenorphine hydrochloride.43. The pharmaceutical dosage form of claim 41 , further comprising hydroxypropylmethylcellulose44. The pharmaceutical dosage form of claim 41 , further comprising a sugar derived alcohol.45. The pharmaceutical dosage form of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of at least about 60 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid.46. The pharmaceutical dosage form of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of at least about 120 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid.47. The pharmaceutical dosage ...

Подробнее
Номер записи: 23
01-01-2015 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20150005333A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A controlled release oral dosage form comprising:a mixture comprising (i) hydrocodone or a pharmaceutically acceptable salt thereof; and(ii) a gelling agent comprising hydroxypropylmethylcellulose, the gelling agent in an effective amount to impart a viscosity of at least about 10 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid;the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.42. The controlled release oral dosage form of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of at least about 60 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid.43. The controlled release oral dosage form of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of at least about 120 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid.44. The controlled release oral dosage form of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of at least about 375 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ...

Подробнее
Номер записи: 24
14-01-2016 дата публикации

PHARMACEUTICAL FORMULATION CONTAINING OPIOID AGONIST, OPIOID ANTAGONIST AND GELLING AGENT

Номер: US20160008350A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic, an opioid antagonist and one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid. 132-. (canceled)33. A controlled release oral dosage form comprising:a therapeutically effective amount of an opioid analgesic,an opioid antagonist,a gelling agent, andone or more pharmaceutically acceptable hydrophobic material(s) selected from the group consisting of cellulose polymers, acrylic polymers, polylactic acid, polyglycolic acid and a co-polymer of the polylactic acid and polyglycolic acid,wherein the gelling agent is in an effective amount to impart a viscosity unsuitable for injection to the dosage form when the dosage form is dissolved in from about 0.5 ml to about 10 ml of an aqueous liquid,a weight ratio of the gelling agent to the opioid analgesic is from about 1:40 to about 40:1, andthe gelling agent is polyethylene oxide.34. The dosage form of claim 33 , wherein the viscosity unsuitable for injection is at least 10 Cp.35. The dosage form of claim 33 , wherein the viscosity unsuitable for injection is at least 60 cP.36. The dosage form of claim 33 , wherein the viscosity unsuitable for injection is from 10 cP to 60 cP.37. The dosage form of claim 33 , wherein the dosage form provides pain relief for at least about 12 hours when orally administered intact to a human patient.38. The oral dosage form of claim 33 , wherein the opioid analgesic is selected from the group consisting of oxycodone claim 33 , codeine claim 33 , hydrocodone claim 33 , hydromorphone claim 33 , levorphanol claim 33 , meperidine claim 33 , morphine claim ...

Подробнее
Номер записи: 25
17-01-2019 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20190015341A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A method of treating pain comprising administering to a patient in need thereof an abuse deterrent controlled release oral dosage form comprising:a matrix comprising oxycodone or a pharmaceutically acceptable salt thereof, a copolymer comprising trimethyl ammonioethyl methacrylate, and a gelling agent comprising polyethylene oxide and microcrystalline cellulose; anda coating over the matrix, the coating comprising a mixture comprising an aminoalkyl methacrylate copolymer, sodium lauryl sulfate, talc and simethicone;wherein the oxycodone or pharmaceutically acceptable salt thereof is the sole active agent in the dosage form,the abuse deterrent dosage form forming a gel when subjected to tampering comprising dissolution in from about 0.5 ml to about 10 ml of an aqueous liquid;the dosage form having a ratio of gelling agent to oxycodone or pharmaceutically acceptable salt thereof from about 8:1 to about 1:8; andthe dosage form providing a therapeutic effect for about 12 hours or longer when orally administered to a human patient.42. The method of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of about 10 cP or more to the gel.43. The method of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of about 60 cP or more to the ...

Подробнее
Номер записи: 26
26-01-2017 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20170020863A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A controlled release oral dosage form comprising:(i) an opioid analgesic;(ii) a gelling agent comprising an emulsifier; and(iii) a fatty acid ester;the dosage form having a ratio of emulsifier to opioid analgesic from about 15:1 to about 1:1 by weight;wherein after oral administration of the dosage form to a human patient, the dosage form provides a therapeutic effect for at least 12 hours; andwherein the dosage form has a viscosity of at least 10 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 ml to about 10 ml of an aqueous liquid.42. The controlled release oral dosage form of claim 41 , wherein the ratio of emulsifier to opioid analgesic is from about 8:1 to about 1:1 by weight.43. The controlled release oral dosage form of claim 41 , wherein the ratio of emulsifier to opioid analgesic is from about 8:1 to about 2:1 by weight.44. The controlled release oral dosage form of claim 41 , wherein the ratio of emulsifier to opioid analgesic is from about 8:1 to about 5:1 by weight.45. The controlled release oral dosage form of claim 41 , further comprising a cellulosic polymer.46. The controlled release oral dosage form of claim 45 , wherein the cellulosic polymer is hydroxyethylcellulose.47. The controlled release oral dosage form of claim 41 , further ...

Подробнее
Номер записи: 27
26-01-2017 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20170020864A1
Автор: Benjamin Oshlack, Christopher Breder, Curtis Wright
Принадлежит: PF Laboratories Inc, Purdue Pharmaceuticals LP

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Подробнее
Номер записи: 28
25-01-2018 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20180021262A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A solvent system comprising:(a) a solvent; and (i) an opioid analgesic in an effective amount to provide an analgesic effect upon oral administration;', '(ii) an emulsifier;', '(iii) a fatty acid ester;', '(iv) a cellulosic polymer; and', '(v) silicon dioxide., '(b) a solute comprising42. The solvent system of claim 41 , having a ratio of emulsifier to opioid analgesic from about 15:1 to about 1:1 by weight.43. The solvent system of claim 42 , wherein the ratio of emulsifier to opioid analgesic is from about 8:1 to about 1:1 by weight.44. The solvent system of claim 42 , wherein the ratio of emulsifier to opioid analgesic is from about 8:1 to about 2:1 by weight.45. The solvent system of claim 42 , wherein the ratio of emulsifier to opioid analgesic is from about 8:1 to about 5:1 by weight.46. The solvent system of claim 41 , wherein the cellulosic polymer is hydroxyethylcellulose.47. The solvent system of claim 41 , further comprising cellulose acetate butyrate.48. The solvent system of claim 41 , wherein the solvent system comprises triacetin.49. The solvent system of claim 41 , further comprising a surfactant.50. The solvent system of claim 41 , wherein the solvent system comprises triacetin and a surfactant.51. The solvent system of claim 41 , wherein the opioid analgesic comprises ...

Подробнее
Номер записи: 29
25-01-2018 дата публикации

Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent

Номер: US20180021330A1
Автор: Benjamin Oshlack, Christopher Breder, Curtis Wright
Принадлежит: PF Laboratories Inc, Purdue Pharma LP, Purdue Pharmaceuticals LP

Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic, an opioid antagonist and one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid.

Подробнее
Номер записи: 30
17-04-2014 дата публикации

FORMULATIONS OF LOW DOSE DICLOFENAC AND BETA-CYCLODEXTRIN

Номер: US20140107209A1
Автор: Carr Daniel B., Mermelstein Fred H., WRIGHT Curtis
Принадлежит:

The present invention is directed to a pharmaceutical composition containing a unit dose of a diclofenac compound effective to induce analgesia; and a beta-cyclodextrin compound; wherein the dose of the diclofenac compound is less than 10 mg. The present invention is also directed to methods of treating a subject in need of analgesia with the pharmaceutical compositions of the invention. 1. A pharmaceutical composition comprising:(a) an amount of a diclofenac compound effective to induce an analgesic effect of at 1 38% on a Visual Analog Scale, wherein the amount does not exceed about 37.5 mg; and(b) a beta-cyclodextrin compound,wherein the pharmaceutical composition is an intravenous formulation.2. The pharmaceutical composition of claim 1 , wherein the diclofenac compound is diclofenac sodium.3. The pharmaceutical composition of claim 1 , wherein the cyclodextrin compound is 2-hydroxypropyl-beta-cyclodextrin.4. The pharmaceutical composition of claim 1 , wherein the dose diclofenac compound is about 37.5 mg.5. The pharmaceutical composition of claim 1 , wherein the dose diclofenac compound is about 18.75 mg.6. The pharmaceutical composition of claim 1 , wherein the dose diclofenac compound is less than about 10 mg.7. The pharmaceutical composition of claim 6 , wherein the dose diclofenac compound is about 9.4 mg.8. The pharmaceutical composition of claim 6 , wherein the dose diclofenac compound is about 5 mg.9. The pharmaceutical composition of claim 6 , wherein the dose diclofenac compound is about 3.75 mg.10. The pharmaceutical composition of claim 1 , further comprising a stabilizer. This application claims priority under 35 U.S.C. §119, based on U.S. Provisional Application Ser. No. 60/786,486, filed Mar. 28, 2006, the disclosure of which is incorporated herein by reference in its entirety.The present invention is directed to pharmaceutical compositions and methods of treating a subject in need of analgesia with pharmaceutical compositions which contain ...

Подробнее
Номер записи: 31
04-02-2016 дата публикации

ONCE-A-DAY OXYCODONE FORMULATIONS

Номер: US20160030419A1
Автор: OSHLACK Benjamin, Prater Derek, WRIGHT Curtis
Принадлежит:

The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C/Coxycodone ratio of 0.6 to 1.0 or 0.7 to 1 after oral administration at steady state to patients and methods thereof. 171-. (canceled)72. A sustained-release oral dosage form for once-a-day administration comprising:a plurality of units containing one or more active agents and one or more excipients, whereinone of the active agents is oxycodone or a pharmaceutically acceptable salt thereof, andthe excipients comprise a sustained release material comprising ethylcellulose, a methacrylic acid copolymer or a mixture thereof,wherein the amount of the oxycodone or pharmaceutically acceptable salt thereof in the dosage form is from about 10 to about 320 mg,{'sub': 24', 'max', 'max, 'the dosage form provides a mean C/Coxycodone ratio of from 0.6 to 1.0 and a mean Tof oxycodone of about 6.5 to about 17 hours after steady state oral administration to humans on a once-a-day basis, and'}the dosage form is a capsule.73. The dosage form of claim 72 , wherein the excipients are selected from the group consisting of (i) the sustained release material; (ii) cellulose ethers claim 72 , (iii) hydroxyalkylcellulose; (iv) plasticizers; (v) talc; and (vi) antioxidants.74. The dosage form of claim 72 , providing a mean C/Coxycodone ratio of about 0.7 to 0.99 after administration at steady state to said humans.75. The dosage form of claim 74 , providing a mean C/Coxycodone ratio of 0.7 to 0.95 after administration at steady state to said humans.76. The dosage form of claim 72 , providing a mean Tof oxycodone at about 8 to about 16 hours after administration at steady state to said humans.77. A sustained-release oral dosage form for once-a-day administration comprising a plurality of units comprising:oxycodone or a pharmaceutically acceptable salt thereof,a sustained release material comprising ethylcellulose, a methacrylic acid copolymer, a ...

Подробнее
Номер записи: 32
29-01-2015 дата публикации

Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent

Номер: US20150031718A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic, an opioid antagonist and one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid. 140-. (canceled)41. A pharmaceutical dosage form comprising:a mixture comprising (i) buprenorphine or a pharmaceutically acceptable salt thereof;(ii) naloxone or a pharmaceutically acceptable salt thereof; and(iii) a gelling agent comprising polyethylene oxide, the gelling agent in an effective amount to impart a viscosity of at least about 10 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid;the dosage form providing an immediate release upon administration to a human patient.42. The pharmaceutical dosage form of claim 41 , further comprising buprenorphine hydrochloride.43. The pharmaceutical dosage form of claim 41 , further comprising naloxone hydrochloride.44. The pharmaceutical dosage form of claim 41 , further comprising hydroxypropylmethylcellulose.45. The pharmaceutical dosage form of claim 41 , further comprising a sugar derived alcohol.46. The pharmaceutical dosage form of claim 41 , wherein the naloxone or pharmaceutically acceptable salt thereof is in an amount that is parenterally effective47. The pharmaceutical dosage form of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of at least about 60 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid.48. The pharmaceutical dosage form of claim 41 , wherein the viscosity is measured using a Brookfield Synchro-Lectric ...

Подробнее
Номер записи: 33
15-02-2018 дата публикации

TAMPER RESISTANT ORAL OPIOID AGONIST FORMULATIONS

Номер: US20180042859A1
Автор: HADDOX J. David, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Oral dosage forms containing an opioid antagonist in a sequestered form are described. The opioid antagonist is sequestered such that it is not released or substantially not released in the gastrointestinal tract from the dosage form which is administered orally intact. However, when the dosage form is chewed, crushed, heated or dissolved in a solvent, and then administered orally, intranasally, parenterally or sublingually, the opioid antagonist is released and at least partially blocks effects of the opioid agonist. 161-. (canceled)62. An oral dosage form comprising:an opioid agonist, andmultiparticulates comprising an opioid antagonist and a sequestering material, the sequestering material separating the opioid antagonist from the opioid agonist,wherein the multiparticulates are dispersed in a matrix comprising the opioid agonist, and the opioid antagonist is substantially not releasable from the dosage form which is administered orally intact.63. The dosage form of claim 62 , wherein the dosage form is a compressed tablet.64. The dosage form of claim 62 , wherein the opioid antagonist comprises naltrexone or a pharmaceutically acceptable salt thereof.65. The dosage form of claim 62 , wherein the opioid agonist is selected from the group consisting of hydrocodone claim 62 , hydromorphone claim 62 , morphine claim 62 , oxycodone claim 62 , oxymorphone claim 62 , and pharmaceutically acceptable salts thereof.66. The dosage form of claim 62 , wherein the sequestering material comprises an ammonio methacrylate copolymer.67. The dosage form of claim 62 , wherein the dosage form comprises oxycodone or a pharmaceutically acceptable salt thereof.68. The dosage form of claim 67 , which comprises 10 mg claim 67 , 20 mg claim 67 , 40 mg claim 67 , or 80 mg oxycodone hydrochloride.69. The dosage form of claim 62 , which comprises from about 10 ng to 275 mg naltrexone.70. The dosage form of claim 69 , which comprises from 0.4 to 12.8 mg naltrexone.71. The dosage form of claim ...

Подробнее
Номер записи: 34
03-03-2016 дата публикации

Pharmaceutical formulation containing gelling agent

Номер: US20160058716A1
Автор: Benjamin Oshlack, Christopher Breder, Curtis Wright
Принадлежит: Benjamin Oshlack, Christopher Breder, Curtis Wright

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Подробнее
Номер записи: 35
01-03-2018 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20180055771A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A controlled release oral solid dosage form comprising:(i) a first population of particles comprising morphine or a pharmaceutically acceptable salt thereof and(ii) a second population of particles comprising polyethylene oxide,the dosage form providing a therapeutic effect for about 12 hours to about 24 hours when orally administered to a human patient,whereinthe particles of the first population are free from polyethylene oxide,the particles of the second population are coated with a coating comprising a cellulose polymer or an acrylic polymer, andthe coating and the particles of the second population are free from said morphine or pharmaceutically acceptable salt thereof.42. The controlled release oral solid dosage form of claim 41 , wherein the particles of the second population further comprise polyvinylpyrrolidone.43. The controlled release oral solid dosage form of claim 41 , wherein the first population of particles and the second population of particles are contained in a pharmaceutically acceptable capsule.44. The controlled release oral solid dosage form of claim 43 , wherein the particles of the first population have a diameter from about 0.5 mm to about 2 mm.45. The controlled release oral solid dosage form of claim 41 , wherein the particles of the second population have a ...

Подробнее
Номер записи: 36
09-03-2017 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20170065524A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. An oral dosage form comprising:(i) an opioid agonist; and(ii) a gelling agent selected from the group consisting of microcrystalline cellulose, a cellulosic polymer and a combination thereof, the gelling agent is in an effective amount to impart a viscosity unsuitable for parenteral administration when the dosage form is subjected to tampering by dissolution in from about 0.5 ml to about 10 ml of an aqueous liquid;the oral dosage form having a ratio of gelling agent to opioid agonist from about 40:1 to about 1:40;the oral dosage form providing an immediate release when orally administered to a human patient.42. The oral dosage form of claim 41 , wherein the cellulosic polymer comprises sodium carboxymethylcellulose.43. The oral dosage form of claim 41 , wherein the gelling agent comprises microcrystalline cellulose and the cellulosic polymer.44. The oral dosage form of claim 43 , wherein the cellulosic polymer comprises sodium carboxymethylcellulose.45. The oral dosage form of claim 41 , wherein the gelling agent further comprises polyvinyl pyrrolidone.46. The oral dosage form of claim 42 , wherein the gelling agent comprises microcrystalline cellulose claim 42 , sodium carboxymethylcellulose and polyvinyl pyrrolidone.47. The oral dosage form of claim 46 , further comprising lactose.48. The ...

Подробнее
Номер записи: 37
09-03-2017 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20170065525A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A method of preparing an oral dosage form comprising:preparing a mixture comprising: (i) an opioid agonist; and (ii) a gelling agent selected from the group consisting of microcrystalline cellulose, a cellulosic polymer and a combination thereof, the gelling agent is in an effective amount to impart a viscosity unsuitable for parenteral administration when the dosage form is subjected to tampering by dissolution in from about 0.5 ml to about 10 ml of an aqueous liquid;compressing the mixture into an oral dosage form;the oral dosage form having a ratio of gelling agent to opioid agonist from about 40:1 to about 1:40;the oral dosage form providing an immediate release when orally administered to a human patient.42. The method of claim 41 , wherein the cellulosic polymer comprises sodium carboxymethylcellulose.43. The method of claim 41 , wherein the gelling agent comprises microcrystalline cellulose and the cellulosic polymer.44. The method of claim 43 , wherein the cellulosic polymer comprises sodium carboxymethylcellulose.45. The method of claim 41 , wherein the gelling agent further comprises polyvinyl pyrrolidone.46. The method of claim 42 , wherein the gelling agent comprises microcrystalline cellulose claim 42 , sodium carboxymethylcellulose and polyvinyl pyrrolidone.47. The method of ...

Подробнее
Номер записи: 38
07-03-2019 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20190070119A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A solvent system comprising:(a) a solvent; and (i) oxycodone or a pharmaceutically acceptable salt thereof;', '(ii) an emulsifier;', '(iii) a fatty acid ester;', '(iv) a cellulosic polymer; and', '(v) silicon dioxide., '(b) a solute comprising42. The solvent system of claim 41 , having a ratio of emulsifier to oxycodone or pharmaceutically acceptable salt thereof from about 15:1 to about 1:1 by weight.43. The solvent system of claim 42 , wherein the ratio of emulsifier to oxycodone or pharmaceutically acceptable salt thereof is from about 8:1 to about 1:1 by weight.44. The solvent system of claim 42 , wherein the ratio of emulsifier to oxycodone or pharmaceutically acceptable salt thereof is from about 8:1 to about 2:1 by weight.45. The solvent system of claim 42 , wherein the ratio of emulsifier to oxycodone or pharmaceutically acceptable salt thereof is from about 8:1 to about 5:1 by weight.46. The solvent system of claim 41 , wherein the cellulosic polymer is hydroxyethylcellulose.47. The solvent system of claim 41 , further comprising cellulose acetate butyrate.48. The solvent system of claim 41 , wherein the solvent system comprises triacetin.49. The solvent system of claim 41 , further comprising a surfactant.50. The solvent system of claim 41 , wherein the solvent system comprises ...

Подробнее
Номер записи: 39
19-03-2015 дата публикации

PHARMACEUTICAL COMBINATIONS OF HYDROCODONE AND NALTREXONE

Номер: US20150080423A1
Автор: BREDER Chris, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed is a pharmaceutical composition comprising from about 5 to about 20 mg of hydrocodone or a pharmaceutically acceptable salt thereof and from 0.055 to about 0.56 mg naltrexone or pharmaceutically acceptable salt thereof. 1. A pharmaceutical composition comprising about 5 to about 20 mg hydrocodone or pharmaceutically acceptable salt thereof and 0.055 to 0.56 mg naltrexone or pharmaceutically acceptable salt thereof , said naltrexone or pharmaceutically acceptable salt thereof and said hydrocodone or pharmaceutically acceptable salt thereof in a ratio of from 0.011:1 to 0.028:1.2. The pharmaceutical composition of comprising about 5 mg hydrocodone or pharmaceutically acceptable salt thereof and from 0.055 mg to 0.14 mg of naltrexone or pharmaceutically acceptable salt thereof.3. The pharmaceutical composition of comprising about 7.5 mg hydrocodone or pharmaceutically acceptable salt thereof and from 0.0825 mg to 0.21 mg of naltrexone or pharmaceutically acceptable salt thereof.4. The pharmaceutical composition of comprising about 10 mg hydrocodone or pharmaceutically acceptable salt thereof and from 0.11 mg to 0.28 mg of naltrexone or pharmaceutically acceptable salt thereof.5. The pharmaceutical composition of comprising about 15 mg hydrocodone or pharmaceutically acceptable salt thereof and from 0.165 mg to 0.42 mg of naltrexone or pharmaceutically acceptable salt thereof.6. The pharmaceutical composition of comprising about 20 mg hydrocodone or pharmaceutically acceptable salt thereof and from 0.22 mg to 0.56 mg of naltrexone or pharmaceutically acceptable salt thereof.7. The pharmaceutical composition of comprising about 5 mg hydrocodone or pharmaceutically acceptable salt thereof and 0.0625 mg of naltrexone or pharmaceutically acceptable salt thereof.8. The pharmaceutical composition of comprising about 7.5 mg hydrocodone or pharmaceutically acceptable salt thereof and 0.09375 mg of naltrexone or pharmaceutically acceptable salt thereof.9. The ...

Подробнее
Номер записи: 40
02-04-2015 дата публикации

TRIPLE SUM FREQUENCY COHERENT MULTIDIMENSIONAL IMAGING

Номер: US20150092190A1
Автор: Boyle Erin Selene, Wright John Curtis
Принадлежит:

Methods of obtaining a multidimensional image of a sample are provided comprising (a) directing a first coherent light pulse having a first frequency ωand a first wave vector kat a first location in the sample, (b) directing a second coherent light pulse having a second frequency ωand a second wave vector kat the first location, (c) directing a third coherent light pulse having a third frequency ωand a third wave vector kat the first location and (d) detecting a coherent output signal having a fourth frequency ωand a fourth wave vector k. At least two, but optionally all three, of the coherent light pulses each excite a different transition to a discrete quantum state (e.g., transitions to vibrational states or to electronic states) of a molecule or molecular functionality in the sample. Steps (a)-(d) are repeated at a sufficient number of other locations in the sample to provide the multidimensional image. 1. A method of obtaining a multidimensional image of a sample , the method comprising:{'sub': 1', '1, '(a) directing a first coherent light pulse having a first frequency ωand a first wave vector kat a first location in a sample,'}{'sub': 2', '2, '(b) directing a second coherent light pulse having a second frequency ωand a second wave vector kat the first location,'}{'sub': 3', '3, '(c) directing a third coherent light pulse having a third frequency ωand a third wave vector kat the first location and'}{'sub': 4', '4, '(d) detecting a coherent output signal having a fourth frequency ωand a fourth wave vector kfrom the first location,'}{'sub': 4', '1', '2', '3', '4', '1', '2', '3, 'wherein ω=±ω±ω±ωand k=±k±k±k,'}wherein at least two of the coherent light pulses each are configured to excite a different transition to a discrete quantum state of a molecule or molecular functionality in the sample,and further wherein steps (a)-(d) are repeated at a sufficient number of other locations in the sample to provide the multidimensional image.2. The method of claim 1 , ...

Подробнее
Номер записи: 41
16-04-2015 дата публикации

FORMULATIONS OF LOW DOSE DICLOFENAC AND BETA-CYCLODEXTRIN

Номер: US20150105467A1
Автор: Carr Daniel B., Mermelstein Fred H., WRIGHT Curtis
Принадлежит: JAVELIN PHARMACEUTICALS, INC.

The present invention is directed to a pharmaceutical composition containing a unit dose of a diclofenac compound effective to induce analgesia; and a beta-cyclodextrin compound; wherein the dose of the diclofenac compound is less than 10 mg. The present invention is also directed to methods of treating a subject in need of analgesia with the pharmaceutical compositions of the invention. 1. A pharmaceutical composition comprising from about 18.75 mg to about 37.5 mg of a diclofenac compound solubilized with a beta-cyclodextrin compound.2. The pharmaceutical composition of claim 1 , wherein the diclofenac compound is diclofenac sodium.3. The pharmaceutical composition of claim 1 , wherein the beta-cyclodextrin compound is hydroxypropyl beta-cyclodextrin.4. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for a parenteral route of administration.5. The pharmaceutical composition of claim 1 , wherein the dose of the diclofenac compound is about 18.75 mg.6. The pharmaceutical composition of claim 1 , wherein the dose diclofenac compound is about 37.5 mg.7. The pharmaceutical composition of claim 1 , further comprising a stabilizer.8. The pharmaceutical composition of claim 4 , wherein the parenteral route of administration is intravenous or intramuscular.9. The pharmaceutical composition of claim 1 , wherein the composition is stable at room temperature. This application is a continuation of and claims priority to U.S. patent application Ser. No. 13/106,697, filed on May 12, 2011, which is a continuation of U.S. patent application Ser. No. 11/689,931, filed on Mar. 22, 2007, now U.S. Pat. No. 8,580,954, which claims priority under 35 U.S.C. §119, based on U.S. Provisional Application No. 60/786,486, filed on Mar. 28, 2006, the disclosures of which are incorporated herein by reference in their entireties.The present invention is directed to pharmaceutical compositions and methods of treating a subject in need of analgesia ...

Подробнее
Номер записи: 42
23-04-2015 дата публикации

OPIOID AGONIST FORMULATIONS WITH RELEASABLE AND SEQUESTERED ANTAGONIST

Номер: US20150110879A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed are oral dosage forms, comprising (i) a therapeutically effective amount of an opioid agonist; (ii) an opioid antagonist in releasable form; and (iii) a sequestered opioid antagonist which is not released when the dosage form is administered intact, and methods thereof. 1. An oral dosage form , comprising(i) a therapeutically effective amount of an opioid agonist;(ii) an opioid antagonist in releasable form; and(iii) a sequestered opioid antagonist which is not released when the dosage form is administered intact.2. An oral dosage form , comprising(i) a first component comprising a therapeutically effective amount of an opioid agonist;(ii) a second component comprising an opioid antagonist in releasable form; and(iii) a third component comprising a sequestered opioid antagonist which is not released when the dosage form is administered intact.3. An oral dosage form , comprising(i) a first component comprising a therapeutically effective amount of an opioid agonist;(ii) a second component comprising an opioid antagonist in releasable form, and a sequestered opioid antagonist which is not released when the dosage form is administered intact.4. An oral dosage form , comprising(i) a first component comprising a therapeutically effective amount of an opioid agonist and an opioid antagonist in releasable form; and(ii) a second component comprising a sequestered opioid antagonist which is not released when the dosage form is administered intact.5. An oral dosage form , comprising(i) a first component comprising a therapeutically effective amount of an opioid agonist and an opioid antagonist in releasable form; and(ii) a second component comprising a sequestered opioid antagonist which is not substantially released when the dosage form is administered intact.6. An oral dosage form , comprising(i) a first component comprising a therapeutically effective amount of an opioid agonist;(ii) a second component comprising an opioid antagonist in releasable form; and(iii) ...

Подробнее
Номер записи: 43
03-07-2014 дата публикации

OPIOID DOSAGE FORMS HAVING DOSE PROPORTIONAL STEADY STATE CAVE AND AUC AND LESS THAN DOSE PROPORTIONAL SINGLE DOSE CMAX

Номер: US20140187572A1
Автор: Colucci Robert, El-Tahtawy Ahmed, WRIGHT Curtis
Принадлежит: Purdue Pharma L.P.

The present invention relates to a plurality of dosage forms comprising a first dosage form and second dosage form each comprising a therapeutic agent, such as an opioid; wherein the dosage strength of the second dosage form is greater than that of the first dosage form; and wherein the steady state Cand the steady state AUC of the first and second dosage forms are dose proportional and the single dose Cof the second dosage form is less than the minimum level for dose proportionality with respect to the first dosage form. The present invention also relates to methods of administering such dosage forms to a patient, as well as to kits comprising such dosage forms and instructions for administration of the dosage forms to a patient. The inventors believe that the dosage forms and methods of the present invention will lead to improved safety and patient acceptance. 2. The plurality of dosage forms of claim 1 , wherein the first dosage form and the second dosage form each have a single dose AUC and the single dose AUC of the first dosage form and the second dosage form are dose proportional.3. The plurality of dosage forms of claim 2 , wherein the first dosage form and the second dosage form are each oral dosage forms.4. The plurality of dosage forms of claim 3 , wherein the first dosage form and the second dosage form are each controlled release dosage forms.5. The plurality of dosage forms of claim 1 , wherein the first dosage form and the second dosage form are each controlled release dosage forms.6. The plurality of dosage forms of claim 1 , wherein the first dosage form and the second dosage form are each oral dosage forms.7. The plurality of dosage forms of claim 6 , wherein the first dosage form and the second dosage form are each controlled release dosage forms.8. The plurality of dosage forms of claim 1 , wherein the opioid is selected form the group consisting of alfentanil claim 1 , allylprodine claim 1 , alphaprodine claim 1 , anileridine claim 1 , ...

Подробнее
Номер записи: 44
27-04-2017 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20170112765A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A controlled release oral solid dosage form comprising:(i) a first population of particles comprising an opioid analgesic, and(ii) a second population of particles comprising a gelling agent,wherein the particles of the first population are free from the gelling agent, the particles of the second population are free from the opioid analgesic, andwhen exposed to from about 0.5 ml to about 10 ml of water, the dosage form forms a gel that cannot be drawn into an insulin syringe without picking up pockets of air.42. The controlled release oral solid dosage form of claim 41 , wherein the gelling agent is polyethylene oxide.43. The controlled release oral solid dosage form of claim 42 , wherein the particles of the second population comprise an acrylic polymer.44. The controlled release oral solid dosage form of claim 43 , wherein the acrylic polymer is an ammonio methacrylate copolymer.45. The controlled release oral solid dosage form of claim 41 , wherein the particles of the second population comprise polyvinylpyrrolidone.46. The controlled release oral solid dosage form of claim 41 , wherein the dosage form provides the therapeutic effect for about 12 hours.47. The controlled release oral solid dosage form of claim 41 , wherein the particles of the first population and the particles of the ...

Подробнее
Номер записи: 45
18-04-2019 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20190110996A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A method of preparing an abuse deterrent controlled release dosage form comprising:{'sub': 12', '40, 'combining oxycodone or a pharmaceutically acceptable salt thereof, a surfactant, a Cto Cfatty acid or a mixture thereof, and a wax comprising carnauba wax or beeswax or a mixture thereof, to form a combination;'}preparing particles from the combination; andcontaining the particles in a capsule;the abuse deterrent dosage form providing a therapeutic effect for about 12 hours or longer when orally administered to a human patient, andthe abuse deterrent dosage form being abuse deterrent when subjected to tampering comprising heating at a temperature greater than about 45° C.42. The method of claim 41 , wherein the particles comprise an organic acid salt of oxycodone.43. The method of claim 41 , wherein the oxycodone or pharmaceutically acceptable salt thereof is oxycodone base.44. The method of claim 41 , wherein the wax comprises carnauba wax.45. The method of claim 41 , wherein the wax comprises beeswax.46. The method of claim 41 , wherein the wax comprises carnauba wax and beeswax.47. A method of preparing an abuse deterrent controlled release dosage form comprising:{'sub': 12', '40, 'combining oxycodone or a pharmaceutically acceptable salt thereof, polyethylene glycol, a fatty acid ...

Подробнее
Номер записи: 46
17-07-2014 дата публикации

Abuse resistant opioid containing transdermal systems

Номер: US20140199383A1
Автор: Anthony E. Carpanzano, Benjamin Oshlack, Bruce E. Reidenberg, Curtis Wright, Ihor Shevchuk, James P. Cassidy, Lino Tavares, Mark A. Alfonso, Rampurna P. Gullapalli, Richard S. Sackler
Принадлежит: Purdue Pharma LP

The present invention relates to transdermal dosage form (FIGS. 1 - 3 ) comprising at least one activating agent and at least one inactivating agent. The dosage form (FIGS. 1 - 3 ) releases the inactivating agent upon disruption of the dosage form (FIGS. 1 - 3 ) thereby preventing or hindering misuse of the active agent contained in the dosage form (FIGS. 1 - 3 ).

Подробнее
Номер записи: 47
04-05-2017 дата публикации

TAMPER RESISTANT ORAL OPIOID AGONIST FORMULATIONS

Номер: US20170119685A1
Автор: HADDOX J. David, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Oral dosage forms containing an opioid antagonist in a sequestered form are described. The opioid antagonist is sequestered such that it is not released or substantially not released in the gastrointestinal tract from the dosage form which is administered orally intact. However, when the dosage form is chewed, crushed, heated or dissolved in a solvent, and then administered orally, intranasally, parenterally or sublingually, the opioid antagonist is released and at least partially blocks effects of the opioid agonist. 161-. (canceled)62: An oral dosage form comprising:an opioid agonist selected from the group consisting of hydrocodone, hydromorphone, morphine, oxycodone, oxymorphone, and pharmaceutically acceptable salts thereof, andnaltrexone hydrochloride sequestered such that 0.5 mg or more of naltrexone is released at 1 hour from the oral dosage form that is crushed, as measured by USP Type II (paddle) apparatus at 75 rpm at 37° C. in 900 ml of Simulated Gastric Fluid, but is substantially non-releasable from the oral dosage form that is administered orally intact.63: The dosage form of claim 62 , wherein the dosage form is a tablet.64: The dosage form of claim 63 , wherein naltrexone hydrochloride is coated with a coating comprising a sequestering material claim 63 , and the coating separates the opioid antagonist from the opioid agonist.65: The dosage form of claim 63 , wherein the sequestering material comprises an ammonio methacrylate copolymer.66: The dosage form of claim 65 , comprising an additional coating comprising at least one pharmaceutically acceptable excipient coated over the coating comprising the sequestering material.67: The dosage form of claim 62 , comprising from about 2.5 mg to about 800 mg of the opioid agonist.68: The dosage form of claim 67 , comprising 10 mg claim 67 , 20 mg claim 67 , 40 mg claim 67 , or 80 mg oxycodone hydrochloride.69: The dosage form of claim 62 , comprising from about 10 ng to 275 mg naltrexone.70: The dosage form ...

Подробнее
Номер записи: 48
25-04-2019 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20190117580A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A controlled release oral solid dosage form comprising:(i) a first population of particles comprising dextroamphetamine or a pharmaceutically acceptable salt thereof and(ii) a second population of particles comprising polyethylene oxide,the dosage form providing a therapeutic effect for about 12 hours to about 24 hours when orally administered to a human patient,whereinthe particles of the first population are free from polyethylene oxide,the particles of the second population are coated with a coating comprising a cellulose polymer or an acrylic polymer, andthe coating and the particles of the second population are free from said dextroamphetamine or pharmaceutically acceptable salt thereof.42. The controlled release oral solid dosage form of claim 41 , wherein the particles of the second population further comprise polyvinylpyrrolidone.43. The controlled release oral solid dosage form of claim 41 , wherein the first population of particles and the second population of particles are contained in a pharmaceutically acceptable capsule.44. The controlled release oral solid dosage form of claim 43 , wherein the particles of the first population have a diameter from about 0.5 mm to about 2 mm.45. The controlled release oral solid dosage form of claim 41 , wherein the particles of the second ...

Подробнее
Номер записи: 49
10-05-2018 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20180125788A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. An oral dosage form comprising:a compressed mixture comprising: (i) an opioid agonist; and (ii) a gelling agent selected from the group consisting of microcrystalline cellulose, a cellulosic polymer and a combination thereof;the oral dosage form having a ratio of gelling agent to opioid agonist from about 40:1 to about 1:40;the oral dosage form providing an immediate release when orally administered to a human patient.42. The oral dosage form of claim 41 , wherein the cellulosic polymer comprises sodium carboxymethylcellulose.43. The oral dosage form of claim 41 , wherein the gelling agent comprises microcrystalline cellulose and the cellulosic polymer.44. The oral dosage form of claim 43 , wherein the cellulosic polymer comprises sodium carboxymethylcellulose.45. The oral dosage form of claim 41 , wherein the gelling agent further comprises polyvinyl pyrrolidone.46. The oral dosage form of claim 42 , wherein the gelling agent comprises microcrystalline cellulose claim 42 , sodium carboxymethylcellulose and polyvinyl pyrrolidone.47. The oral dosage form of claim 46 , wherein the compressed mixture further comprises lactose.48. The oral dosage form of claim 46 , wherein the compressed mixture further comprises magnesium stearate.49. The oral dosage form of claim 46 , wherein the compressed ...

Подробнее
Номер записи: 50
31-07-2014 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20140213606A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A therapeutic pharmaceutical composition comprising: a mixture including (a) a water soluble drug susceptible to abuse; (b) a gel-forming polymer; (c) a disintegrant; and (d) a surfactant; wherein the pharmaceutical composition exhibits an immediate release profile.42. The therapeutic pharmaceutical composition of claim 41 , wherein the pharmaceutical composition is in unit dose form.43. The therapeutic pharmaceutical composition of claim 41 , wherein the pharmaceutical composition is in suppository claim 41 , capsule claim 41 , pill claim 41 , soft gelatin capsule claim 41 , or compressed tablet form.44. The therapeutic pharmaceutical composition of claim 41 , wherein the water soluble drug susceptible to abuse is present in an amount of 2.3 to 29.8 wt % of the composition.45. The therapeutic pharmaceutical composition of claim 41 , wherein the disintegrant is present in an amount of 5 to 15 wt % of the composition.46. The therapeutic pharmaceutical composition of claim 41 , wherein the surfactant is present in an amount of 1 to 10 wt % of the composition.47. The therapeutic pharmaceutical composition of claim 41 , wherein the gel-forming polymer is present in an amount of about 3 to about 40 wt % of the composition.48. The therapeutic pharmaceutical composition of claim 41 , wherein the ...

Подробнее
Номер записи: 51
21-05-2015 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20150140083A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A therapeutic pharmaceutical composition comprising: a mixture including (a) an opioid; (b) a gel-forming polymer; (c) a disintegrant; and (d) a surfactant; wherein the pharmaceutical composition exhibits an immediate release profile.42. The therapeutic pharmaceutical composition of claim 41 , wherein the pharmaceutical composition is in unit dose form.43. The therapeutic pharmaceutical composition of claim 41 , wherein the pharmaceutical composition is in suppository claim 41 , capsule claim 41 , pill claim 41 , soft gelatin capsule claim 41 , or compressed tablet form.44. The therapeutic pharmaceutical composition of claim 41 , wherein the water soluble drug susceptible to abuse is present in an amount of 2.3 to 29.8 wt % of the composition.45. The therapeutic pharmaceutical composition of claim 41 , wherein the disintegrant is present in an amount of 5 to 15 wt % of the composition.46. The therapeutic pharmaceutical composition of claim 41 , wherein the surfactant is present in an amount of 1 to 10 wt % of the composition.47. The therapeutic pharmaceutical composition of claim 41 , wherein the gel-forming polymer is present in an amount of about 3 to about 40 wt % of the composition.48. The therapeutic pharmaceutical composition of claim 41 , wherein the disintegrant is selected from the ...

Подробнее
Номер записи: 52
21-05-2015 дата публикации

ONCE-A-DAY OXYCODONE FORMULATIONS

Номер: US20150140095A1
Автор: OSHLACK Benjamin, Prater Derek, WRIGHT Curtis
Принадлежит:

The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C/Coxycodone ratio of 0.6 to 1.0 or 0.7 to 1 after oral administration at steady state to patients and methods thereof. 1. A sustained-release oral dosage form for once-a-day administration comprising:a pharmaceutically acceptable matrix comprising an analgesically effective amount of oxycodone or a pharmaceutically acceptable salt thereof and a sustained release material,{'sub': 24', 'max, 'said dosage form providing an analgesic effect for at least about 24 hours and a mean C/Coxycodone ratio of 0.6 to 1.0 after steady state oral administration to said human patients.'}2. The dosage form of claim 1 , which provides a mean Tof oxycodone at about 2 to about 17 hours after administration at steady state to said patients.3. The dosage form of claim 1 , which provides a mean Tof oxycodone at about 8 to about 16 hours after administration at steady state to said patients.4. The dosage form of claim 1 , which provides a mean Wof oxycodone of between 4 and 24 hours after administration at steady state to said patients.58-. (canceled)9. The dosage form of claim 1 , which provides a mean Tof oxycodone at about 12 to about 16 hours after administration at steady state to said patients.10. The dosage form of claim 1 , wherein said oxycodone or pharmaceutically acceptable salt thereof is in an amount from about 5 to about 640 mg.11. (canceled)12. The dosage form of claim 1 , which provides a mean C/Coxycodone ratio of 0.7 to 0.99 after administration at steady state to said patients.13. The dosage form of claim 1 , which provides a mean C/Coxycodone ratio of 0.8 to 0.95 after administration at steady state to said patients.14. The dosage form of claim 1 , which provides an in-vitro release rate claim 1 , of oxycodone claim 1 , when measured by the USP Basket Method at 100 rpm in 900 ml aqueous buffer at a pH of between 1.6 and 7.2 ...

Подробнее
Номер записи: 53
28-05-2015 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20150147391A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A controlled release oral solid dosage form comprising:matrix multiparticulates comprising (i) oxycodone base, an organic acid salt of oxycodone, or a combination thereof;(ii) a gelling agent comprising a surfactant, an emulsifier or a mixture thereof;{'sub': 12', '40, '(iii) a C-Cfatty acid; and'}(iv) a wax;the matrix multiparticulates providing a therapeutic effect for at least about 12 hours when orally administered to a human patient, having a viscosity of at least about 10 cP when subjected to tampering by heating at a temperature greater than about 45° C., and contained in a pharmaceutically acceptable capsule.42. The controlled release oral solid dosage form of claim 41 , wherein the matrix multiparticulates comprise an organic acid salt of oxycodone.43. The controlled release oral solid dosage form of claim 41 , wherein the matrix multiparticulates comprise oxycodone base.44. The controlled release oral solid dosage form of claim 41 , wherein the wax is selected from the group consisting of carnauba wax claim 41 , beeswax and a combination thereof.45. The controlled release oral solid dosage form of claim 41 , wherein the wax comprises carnauba wax.46. The controlled release oral solid dosage form of claim 41 , wherein the wax comprises beeswax.47. The controlled release oral solid ...

Подробнее
Номер записи: 54
28-05-2015 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20150148319A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 1. An immediate release oral dosage form comprising:a therapeutically effective amount of oxycodone or a pharmaceutically acceptable salt thereof; anda gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is subject to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid;the dosage form providing an immediate release of the oxycodone or pharmaceutically acceptable salt thereof when orally administered to a human patient.28-. (canceled)9. The immediate release oral dosage form of claim 1 , wherein the oxycodone or pharmaceutically acceptable salt thereof is oxycodone hydrochloride.1011-. (canceled)12. The immediate release oral dosage form of claim 9 , wherein the ratio of the gelling agent to the oxycodone hydrochloride is from about 1:40 to about 40:1.13. The immediate release oral dosage form of claim 9 , wherein the ratio of the gelling agent to the oxycodone hydrochloride is from about 1:1 to about 30:1.14. The immediate release oral dosage form of claim 9 , wherein the ratio of the gelling agent to the oxycodone hydrochloride is from about 2:1 to about 10:1.15. The immediate release oral dosage form of claim 1 , wherein ...

Подробнее
Номер записи: 55
14-08-2014 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20140228390A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A controlled release oral dosage form comprising:from about 2.5 mg to about 320 mg oxycodone or a pharmaceutically acceptable salt thereof;acetaminophen; anda gelling agent comprising polyethylene oxide in an effective amount to impart a viscosity of at least about 10 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid;the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.42. The controlled release oral dosage form of claim 41 , wherein the aqueous liquid is water.43. The controlled release oral dosage form of claim 41 , wherein the viscosity is imparted when the dosage form is subjected to tampering by dissolution in about 1 ml to about 3 ml of aqueous liquid.44. The controlled release oral dosage form of claim 41 , wherein a viscosity of at least about 60 cP is imparted.45. The controlled release oral dosage form of claim 41 , wherein the oxycodone or pharmaceutically acceptable salt thereof comprises oxycodone hydrochloride.46. The controlled release oral dosage form of claim 45 , comprising from about 5 mg to about 10 mg oxycodone hydrochloride.47. The controlled release oral dosage form of claim 41 , wherein the viscosity is obtained when the dosage form is ...

Подробнее
Номер записи: 56
02-06-2016 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20160151277A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A method of preparing an abuse deterrent immediate release dosage form comprising:(i) preparing a mixture comprising oxycodone or a pharmaceutically acceptable salt thereof, a disintegrant, sodium lauryl sulfate, magnesium stearate and a gelling agent comprising polyethylene oxide; and(ii) formulating the mixture into an abuse deterrent dosage form that forms a gel when the dosage form is subjected to tampering comprising dissolution in from about 0.5 ml to about 10 ml of an aqueous liquid;the dosage form having a ratio of polyethylene oxide to oxycodone or pharmaceutically acceptable salt thereof from about 1:1 to about 8:1; andthe dosage form providing an immediate release of the oxycodone hydrochloride when orally administered to a human patient.42. The method of claim 41 , wherein the aqueous liquid is water.43. The method of claim 41 , wherein the dosage form forms a gel when the dosage form is subjected to tampering by dissolution in from about 1 to about 3 ml of aqueous liquid is mixed with the crushed dosage form.44. The method of claim 41 , wherein the gel has a viscosity of about 10 cP or more.45. The method of claim 41 , wherein the gel has a viscosity of about 60 cP or more.46. The method of claim 41 , wherein the gel has a viscosity of about 120 cP or more.47. The method of claim ...

Подробнее
Номер записи: 57
02-06-2016 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20160151289A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A method of preparing an abuse deterrent controlled release oral dosage form comprising:preparing a mixture comprising hydrocodone or a pharmaceutically acceptable salt thereof, and a gelling agent comprising polyethylene oxide; andformulating the mixture into an abuse deterrent dosage form that forms a gel when the dosage form is subjected to tampering comprising dissolution in from about 0.5 ml to about 10 ml of an aqueous liquid;the dosage form having a ratio of polyethylene oxide to hydrocodone or pharmaceutically acceptable salt thereof from about 40:1 to about 1:40; andthe dosage form providing a therapeutic effect for about 12 hours or longer when orally administered to a human patient.42. The method of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of about 10 cP or more to the gel.43. The method of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of about 60 cP or more to the gel.44. The method of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of about 120 cP or more to the gel.45. The method of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of about 2 claim 41 ,000 cP or more to the gel.46. The method of claim 41 , wherein the gelling ...

Подробнее
Номер записи: 58
02-06-2016 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20160151290A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A method of preparing an abuse deterrent controlled release dosage form comprising:preparing a mixture of hydrocodone or a pharmaceutically acceptable salt thereof and a gelling agent comprising polyethylene oxide and polyethylene glycol; andformulating the mixture into an abuse deterrent dosage form that forms a gel when the dosage form is subjected to tampering comprising dissolution in from about 0.5 ml to about 10 ml of an aqueous liquid;the dosage form having a ratio of polyethylene oxide to hydrocodone or pharmaceutically acceptable salt thereof from about 40:1 to about 1:40; andthe dosage form providing a therapeutic effect for about 12 hours or longer when orally administered to a human patient.42. The method of claim 41 , wherein the gelling agent further comprises a cellulosic polymer.43. The method of claim 42 , wherein the cellulosic polymer is selected from the group consisting of microcrystalline cellulose claim 42 , sodium carboxymethylcellulose claim 42 , methylcellulose claim 42 , ethylcellulose claim 42 , hydroxyethylcellulose claim 42 , hydroxypropylcellulose claim 42 , hydroxypropylmethylcellulose and combinations thereof.44. The method of claim 42 , wherein the cellulosic polymer comprises microcrystalline cellulose.45. The method of claim 42 , wherein the cellulosic ...

Подробнее
Номер записи: 59
02-06-2016 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20160151291A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A method of preparing an abuse deterrent controlled release dosage form comprising:preparing a mixture of hydrocodone or a pharmaceutically acceptable salt thereof and a gelling agent comprising polyethylene oxide and a cellulosic polymer; andformulating the mixture into an abuse deterrent dosage form that forms a gel when the dosage form is subjected to tampering comprising dissolution in from about 0.5 ml to about 10 ml of an aqueous liquid;the dosage form having a ratio of polyethylene oxide to hydrocodone or pharmaceutically acceptable salt thereof from about 40:1 to about 1:40; andthe dosage form providing a therapeutic effect for about 12 hours or longer when orally administered to a human patient.42. The method of claim 41 , wherein the cellulosic polymer is selected from the group consisting of microcrystalline cellulose claim 41 , sodium carboxymethylcellulose claim 41 , methylcellulose claim 41 , ethylcellulose claim 41 , hydroxyethylcellulose claim 41 , hydroxypropylcellulose claim 41 , hydroxypropylmethylcellulose and combinations thereof.43. The method of claim 42 , wherein the cellulosic polymer is selected from the group consisting of hydroxyethylcellulose claim 42 , hydroxypropylcellulose claim 42 , hydroxypropylmethylcellulose and combinations thereof.44. The method of claim ...

Подробнее
Номер записи: 60
02-06-2016 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20160151297A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A method of preparing an abuse deterrent controlled release dosage form comprising:preparing particles comprising a mixture of hydrocodone or a pharmaceutically acceptable salt thereof, hydroxypropylmethylcellulose, ethylcellulose and a glyceryl ester of a fatty acid;coating each of the particles with a controlled release material comprising ethylcellulose;formulating the coated particles into a dosage form;the dosage form forming a gel when subjected to tampering comprising dissolution in from about 0.5 ml to about 10 ml of an aqueous liquid; andthe dosage form providing a therapeutic effect for about 12 hours or longer when orally administered to a human patient.42. The method of claim 41 , wherein the gel has a viscosity of about 10 cP or more when the dosage form is subjected to tampering by dissolution in from about 0.5 ml to about 10 ml of an aqueous liquid.43. The method of claim 41 , wherein the gel has a viscosity from about 60 cP to about 5 claim 41 ,000 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 ml to about 10 ml of an aqueous liquid.44. The method of claim 41 , comprising from about 75 ng to about 750 mg of hydrocodone or a pharmaceutically acceptable salt thereof.45. The method of claim 44 , wherein the hydrocodone or pharmaceutically ...

Подробнее
Номер записи: 61
02-06-2016 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20160151355A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A method of preparing an abuse deterrent controlled release dosage form comprising:{'sub': 12', '40, 'combining oxycodone or a pharmaceutically acceptable salt thereof, polyglycolyzed glycerides, a Cto Cfatty acid or a mixture thereof, and a wax comprising carnauba wax or beeswax or a mixture thereof, to form a combination;'}preparing particles from the combination; andcontaining the particles in a capsule;the abuse deterrent dosage form providing a therapeutic effect for about 12 hours or longer when orally administered to a human patient, andthe abuse deterrent dosage form being abuse deterrent when subjected to tampering comprising heating at a temperature greater than about 45° C.42. The method of claim 41 , wherein the particles comprise an organic acid salt of oxycodone.43. The method of claim 41 , wherein the oxycodone or pharmaceutically acceptable salt thereof is oxycodone base.44. The method of claim 41 , wherein the wax comprises carnauba wax.45. The method of claim 41 , wherein the wax comprises beeswax.46. The method of claim 41 , wherein the fatty acid comprises Cfatty acid.47. The method of claim 41 , wherein the fatty acid comprises stearic acid.48. The method of claim 41 , wherein the fatty acid comprises Cfatty acid and stearic acid.49. The method of claim 41 , wherein the ...

Подробнее
Номер записи: 62
02-06-2016 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20160151356A1
Автор: Benjamin Oshlack, Christopher Breder, Curtis Wright
Принадлежит: PF Laboratories Inc, Purdue Pharmaceuticals LP

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Подробнее
Номер записи: 63
02-06-2016 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20160151357A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A method of preparing an abuse deterrent controlled release oral dosage form comprising:preparing a mixture comprising oxycodone or a pharmaceutically acceptable salt thereof and a gelling agent comprising polyethylene oxide, a cellulosic polymer or a mixture thereof;formulating the mixture into a matrix;coating the matrix with an aminoalkyl methacrylate copolymer;the abuse deterrent dosage form forming a gel when subjected to tampering comprising dissolution in from about 0.5 ml to about 10 ml of an aqueous liquid;the dosage form having a ratio of gelling agent to oxycodone or pharmaceutically acceptable salt thereof from about 40:1 to about 1:40; andthe dosage form providing a therapeutic effect for about 12 hours or longer when orally administered to a human patient.42. The method of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of about 10 cP or more to the gel.43. The method of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of about 60 cP or more to the gel.44. The method of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of about 120 cP or more to the gel.45. The method of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of about 2 claim ...

Подробнее
Номер записи: 64
02-06-2016 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20160151358A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A method of preparing an abuse deterrent controlled release oral dosage form comprising:preparing a mixture comprising oxycodone or a pharmaceutically acceptable salt thereof and a gelling agent comprising polyethylene oxide;formulating the mixture into a matrix; andapplying a cellulosic polymer to the matrix,the abuse deterrent dosage form forming a gel when subjected to tampering comprising dissolution in from about 0.5 ml to about 10 ml of an aqueous liquid;the dosage form having a ratio of polyethylene oxide to oxycodone or pharmaceutically acceptable salt thereof from about 40:1 to about 1:40; andthe dosage form providing a therapeutic effect for about 12 hours or longer when orally administered to a human patient.42. The method of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of about 10 cP or more to the gel.43. The method of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of about 60 cP or more to the gel.44. The method of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of about 120 cP or more to the gel.45. The method of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of about 2 claim 41 ,000 cP or more to the gel.46. The method of ...

Подробнее
Номер записи: 65
02-06-2016 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20160151360A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A method of preparing a pharmaceutical dosage form comprising:preparing a mixture comprising buprenorphine hydrochloride and a gelling agent comprising polyethylene oxide and hydroxypropylmethylcellulose; andformulating the mixture into a dosage form that provides an immediate release of the buprenorphine hydrochloride upon oral administration to a human patient.42. The method of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of about 10 cP or more when the dosage form is subjected to tampering comprising dissolution in from about 0.5 to about 10 ml of an aqueous liquid.43. The method of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of about 60 cP or more when the dosage form is subjected to tampering comprising dissolution in from about 0.5 to about 10 ml of an aqueous liquid.44. The method of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of about 120 cP or more when the dosage form is subjected to tampering comprising dissolution in from about 0.5 to about 10 ml of an aqueous liquid.45. The method of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of about 375 cP or more when the dosage form is subjected to tampering comprising dissolution ...

Подробнее
Номер записи: 66
02-06-2016 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20160151502A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A method of preparing an abuse deterrent controlled release oral dosage form comprising:preparing a mixture comprising oxycodone or a pharmaceutically acceptable salt thereof and a gelling agent comprising polyethylene oxide and a cellulosic polymer; andformulating the mixture into an abuse deterrent dosage form that forms a gel when the dosage form is subjected to tampering comprising dissolution in from about 0.5 ml to about 10 ml of an aqueous liquid;the dosage form having a ratio of gelling agent to oxycodone or pharmaceutically acceptable salt thereof from about 40:1 to about 1:40;the dosage form providing a therapeutic effect for about 12 hours or longer when orally administered to a human patient.42. The method of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of about 10 cP or more to the gel.43. The method of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of about 60 cP or more to the gel.44. The method of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of about 120 cP or more to the gel.45. The method of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity from about 120 cP to about 5 claim 41 ,000 cP to the gel46. The method of claim 41 , ...

Подробнее
Номер записи: 67
07-05-2020 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20200138720A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A solvent system comprising:(a) a solvent; and (i) oxycodone or pharmaceutically acceptable salt thereof;', '(ii) an emulsifier;', '(iii) a fatty acid ester;', '(iv) a cellulosic polymer; and', '(v) silicon dioxide;, '(b) a solute comprisingthe solvent system having a ratio of emulsifier to oxycodone or pharmaceutically acceptable salt thereof from about 40:1 to about 1:40 by weight.42. The solvent system of claim 41 , having a ratio of emulsifier to oxycodone or pharmaceutically acceptable salt thereof from about 40:1 to about 1:1 by weight.43. The solvent system of claim 41 , wherein the cellulosic polymer is hydroxyethyl cellulose.44. The solvent system of claim 41 , further comprising cellulose acetate butyrate.45. The solvent system of claim 41 , wherein the solvent system comprises triacetin.46. The solvent system of claim 41 , further comprising a surfactant.47. The solvent system of claim 41 , wherein the solvent system comprises triacetin and a surfactant.48. A solvent system comprising:(a) a solvent; and (i) an opioid analgesic in an effective amount to provide an analgesic effect upon oral administration,', '(ii) a gelling agent comprising an emulsifier; and', '(iii) a cellulosic polymer;', 'the solvent system having a ratio of emulsifier to opioid analgesic from about 40:1 to ...

Подробнее
Номер записи: 68
31-05-2018 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20180147151A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. An abuse deterrent controlled release dosage form comprising:an extruded mixture comprising an opioid agonist and a gelling agent selected from the group consisting of polyethylene oxide, a cellulosic polymer and a combination thereof; andthe dosage form having a ratio of gelling agent to opioid agonist from about 40:1 to about 1:40;the dosage form providing a therapeutic effect for about 12 hours or longer when orally administered to a human patient.42. The abuse deterrent controlled release dosage form of claim 41 , wherein the mixture comprises polyethylene and the cellulosic polymer.43. The abuse deterrent controlled release dosage form of claim 41 , wherein the cellulosic polymer is hydroxypropylmethylcellulose.44. The abuse deterrent controlled release dosage form of claim 43 , wherein the gelling agent further comprises polyethylene glycol.45. The abuse deterrent controlled release dosage form of claim 44 , wherein the mixture further comprises alpha-tocopherol.46. The abuse deterrent controlled release dosage form of claim 45 , wherein the dosage form is a compressed tablet.47. The abuse deterrent controlled release dosage form of claim 46 , further comprising coating the tablet with a film.48. The method of claim 45 , wherein the polyethylene oxide has a weight average molecular ...

Подробнее
Номер записи: 69
08-06-2017 дата публикации

PHARMACEUTICAL FORMULATION CONTAINING OPIOID AGONIST, OPIOID ANTAGONIST AND GELLING AGENT

Номер: US20170157115A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic, an opioid antagonist and one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid. 132-.33. A controlled release oral dosage form comprising:a therapeutically effective amount of an opioid analgesic,from about 10 ng to 275 mg of an opioid antagonist, andparticles consisting of a gelling agent, one or more pharmaceutically acceptable hydrophobic material(s) selected from the group consisting of cellulose polymers, acrylic polymers, polylactic acid, polyglycolic acid and a co-polymer of the polylactic acid and polyglycolic acid, and one or more additional pharmaceutically acceptable excipient(s),wherein the gelling agent is releasable from said particles and a solubilized mixture having a viscosity unsuitable for injection is formed when the dosage form is crushed and dissolved in from about 1 to about 5 ml of water,a weight ratio of the gelling agent to the opioid analgesic is from about 1:40 to about 40:1, andthe gelling agent is a gum.34. The dosage form of claim 33 , wherein the viscosity is at least 60 Cp.35. The dosage form of claim 33 , wherein the gum is selected from the group consisting of gum tragacanth claim 33 , gum acacia claim 33 , guar gum claim 33 , xanthan gum claim 33 , locust bean gum claim 33 , tara gum claim 33 , gellan gum claim 33 , welan gum claim 33 , rhamsan gum claim 33 , and mixtures thereof.36. The dosage form of claim 33 , wherein the viscosity is from 10 cP to 60 cP.37. The dosage form of claim 33 , wherein the dosage form provides pain relief for at least about 12 hours when orally administered ...

Подробнее
Номер записи: 70
02-07-2015 дата публикации

TAMPER-RESISTANT ORAL OPIOID AGONIST FORMULATIONS

Номер: US20150182467A1
Автор: Haddox J.David, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Methods of decreasing abuse potentials of oral opioid dosage forms are described. In the methods, an opioid antagonist in a substantially non-releasable form is included in oral dosage forms comprising an opioid agonist. When the dosage form is chewed, crushed, heated or dissolved in a solvent, and then administered orally, intranasally, parenterally or sublingually, the opioid antagonist is released and at least partially blocks effects of the opioid agonist. Methods of preparing oral opioid dosage forms having decreased abuse potential are also described. 161-. (canceled)62. A method of decreasing an abuse potential of an oral opioid dosage form comprising:combining an opioid agonist, an opioid antagonist and one or more pharmaceutically acceptable hydrophobic material(s) into an oral opioid dosage form such that the one or more pharmaceutically acceptable hydrophobic materials substantially prevent the release of the opioid antagonist from the dosage form which is orally delivered to the gastrointestinal tract without having been tampered with, but releases an effective amount of the opioid antagonist from the dosage form which is chewed, crushed, heated, or dissolved in a solvent, and then administered orally, intranasally, parenterally or sublingually so as to at least partially block an effect of the opioid agonist.63. The method of claim 62 , wherein the opioid antagonist is naltrexone or a pharmaceutically acceptable salt thereof.64. The method of claim 63 , wherein the intact dosage form is adapted to release less than 0.5% by weight of the opioid antagonist at 1 hour after oral administration.65. The method of claim 62 , wherein the intact dosage form is adapted to release less than 1% by weight of the opioid antagonist at 36 hours after oral administration.66. The method of claim 63 , wherein the dosage form is adapted to release less than 0.25 mg of naltrexone when intact claim 63 , and 0.25 mg or more of naltrexone when subjected to crushing claim 63 , ...

Подробнее
Номер записи: 71
02-07-2015 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20150182628A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A controlled release oral solid dosage form comprising:(i) controlled release particles comprising a plurality of inert beads coated with hydrocodone bitartrate, the hydrocodone bitartrate coated beads overcoated with an ammonio methacrylate copolymer;(ii) immediate release particles comprising a plurality of inert beads coated with hydrocodone bitartrate and hydroxypropylmethylcellulose;(iii) a gelling agent comprising polyethylene oxide;the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient, and having a viscosity unsuitable for parenteral administration when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid.42. The controlled release oral solid dosage form of claim 41 , wherein the gelling agent is incorporated in the controlled release particles.43. The controlled release oral solid dosage form of claim 41 , wherein the gelling agent is separate from the controlled release particles and the immediate release particles.44. The controlled release oral solid dosage form of claim 43 , wherein the gelling agent is in the form of particles.45. The controlled release oral solid dosage form of claim 44 , wherein the gelling agent particles comprise the gelling agent coated ...

Подробнее
Номер записи: 72
18-09-2014 дата публикации

Antenna and Amplifier Status Monitoring System

Номер: US20140273896A1
Автор: Curtis A. Wright, Ian J. Timmins, John M. Ray
Принадлежит: Optical Cable Corp

A signal conditioning system for a distributed antenna network includes a donor antenna in a first location receiving a downlink radio frequency signal from a radio frequency source. A service antenna is in a second location different from the first location, wherein the service antenna transmits the downlink radio frequency signal to an end user device, and the end user device transmits an uplink radio frequency signal back to the service antenna. Separate gain control amplifiers process the uplink and downlink signals and are located at the separate first and second locations to reduce thermal noise in the uplink and downlink signals. Reduced thermal noise allows quality transmission over optical fibers in addition to coaxial cables. First and second microcontrollers at the first and second locations control respective attenuators and transmit power level data to remote computer processors.

Подробнее
Номер записи: 73
29-07-2021 дата публикации

Splice Sleeve Holder Nest

Номер: US20210231898A1
Автор: Howe Jerry, Seo Sumio, WRIGHT Curtis, Yanik James
Принадлежит: Optical Cable Corporation

A fiber splice cassette includes a main chassis, a removable cover, splice sleeve holders, and four cable clamp boots. The main chassis forms a cavity having a plurality of cable organizing tabs for cable management. Splice sleeve holders are located in the cavity of the main chassis, each of the splice sleeve holders being selectively removable from a corresponding splice sleeve holder nest and being configured for specific splicing capabilities while maintaining the structural strength of the holders. The splice sleeve holder nests may be selectively and removably attached to an interior surface of the fiber cable enclosure via a variety of means to allow the splice sleeve holder nests to be easily rotated, relocated, or accessed for maintenance. 1. A fiber splice cassette for use in combination with an adapter plate bulkhead , the fiber splice cassette comprising:a main chassis forming a cavity;a removable cover which permits access to at least a portion of the main chassis;a plurality of splice sleeve holders and a plurality of splice sleeve nests, wherein each of the plurality of splice sleeve holders is selectively removable from a corresponding one of the plurality of splice sleeve holder nests;a plurality of cable clamp boots;opposing flexible latches on the main chassis, each of the flexible latches having a corresponding protrusion, the opposing flexible latches being structured and disposed for selectively securing the cassette to the adapter plate bulkhead;an angled cable entry point on the main chassis;first and second cable clamp boots each being located in the cavity adjacent the angled cable entry point, each of the first and second cable clamp boots being sized and configured for accommodating cables of different diameters;a straight cable entry point on the main chassis; andthird and fourth cable clamp boots each being located in the cavity adjacent the straight cable entry point, each of the third and fourth cable clamp boots being sized and ...

Подробнее
Номер записи: 74
02-10-2014 дата публикации

SEQUESTERED ANTAGONIST FORMULATIONS

Номер: US20140296276A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит: Purdue Pharma L.P.

Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the mean Cmax of the antagonist after single dose oral administration of the dosage form after tampering to the mean Cmax of antagonist after single dose oral administration of an intact dosage form is at least 1.5:1. 1159-. (canceled)160. An oral dosage form consisting ofan opioid agonist selected from the group consisting of morphine, hydromorphone, hydrocodone, oxycodone, codeine, meperidine, methadone, oxymorphone, and pharmaceutically acceptable salts thereof,an opioid antagonist selected from the group consisting of naltrexone, naloxone and pharmaceutically acceptable salts thereof,one or more hydrophobic materials, andadditional pharmaceutically acceptable excipients, whereinall of the opioid antagonist in the dosage form is sequestered with the one or more hydrophobic materials such that the ratio of the mean Cmax of the opioid antagonist after single dose oral administration of the dosage form after tampering by means of crushing, shearing, grinding, chewing, dissolution in a solvent, heating or any combination thereof to the mean Cmax of the opioid antagonist after single dose oral administration of the dosage form intact is at least 1.5:1.161. The dosage form of claim 160 , wherein said ratio is at least 3:1.162. The dosage form of claim 160 , wherein said ratio is at least 4.5:1.163. The dosage form of claim 160 , wherein said ratio is at least 4.5:1.164. The dosage form of claim 160 , wherein said ratio is at least 8:1.165. The dosage form of claim 164 , wherein said ratio is at least 10:1.166. The dosage form of claim 160 , wherein the opioid agonist is selected from the group consisting of morphine claim 160 , hydromorphone claim 160 , hydrocodone claim 160 , oxycodone claim 160 , oxymorphone claim 160 , pharmaceutically ...

Подробнее
Номер записи: 75
09-10-2014 дата публикации

TITRATABLE DOSAGE TRANSDERMAL DELIVERY SYSTEM

Номер: US20140303571A1
Автор: Wright IV Curtis
Принадлежит:

The present invention relates to a titratable dosage transdermal delivery system for systemic delivery of a therapeutic agent or drug. The system comprises a plurality of patch units that are connected along one or more borders. The plurality of patch units are divisible into units along the one or more borders having one or more lines of separation. Each patch unit is surrounded by a border. The therapeutic patch has at least a backing layer and a therapeutic agent comprising layer. The dosage of therapeutic agent delivered to a patient is proportional to the number of patch unit applied per treatment. The system enables systemic administration of a titratable dosage of therapeutic agent, adjustable by the patient under the direction of a physician, through the skin or mucosa. Moreover, the invention relates to a method of making the titratable dosage transdermal delivery system. Furthermore, the invention relates to a method of providing a titratable amount of therapeutic agent to a patient using the transdermal delivery system of the invention. 1. A method of delivering a drug through a patient's skin comprising:(a) providing a transdermal delivery system that comprises a plurality of patch units, wherein each patch unit comprises a backing layer having one or more borders, a drug layer comprising a drug disposed on the backing layer, and an adhesive layer, wherein the drug is a narcotic analgesic, a local anesthetic, a sedative, a tranquilizer, or a combination thereof, and wherein at least a portion of the adhesive layer is disposed on the borders of the backing layer; the plurality of patch units are connected to each other along one or more borders of the patch units; and each patch unit is defined by one or more lines of separation along the borders of the patch units;(b) separating at least one patch unit from the transdermal delivery system along at least one line of separation; and(c) applying at least one patch unit such that the drug layer makes contact ...

Подробнее
Номер записи: 76
20-08-2015 дата публикации

TAMPER-RESISTANT ORAL OPIOID AGONIST FORMULATIONS

Номер: US20150231086A1
Автор: Haddox J.David, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Oral dosage forms containing an opioid antagonist in a sequestered form are described. The opioid antagonist is sequestered such that it is not released or substantially not released in the gastrointestinal tract from the dosage form which is administered orally intact. However, when the dosage form is chewed, crushed, heated or dissolved in a solvent, and then administered orally, intranasally, parenterally or sublingually, the opioid antagonist is released and at least partially blocks effects of the opioid agonist. 161-. (canceled)62. An oral dosage form comprising:coated beads, each coated bead comprising an inert bead, a coating comprising an opioid antagonist coated over the inert bead, and a coating comprising a sequestering material coated over the coating comprising the opioid antagonist, andan opioid agonist, whereinthe dosage form is a capsule,the opioid agonist is oxycodone or a salt thereof,the opioid antagonist is naltrexone or a salt thereof, and0.25 mg or more of naltrexone is released at 1 hour from the coated beads when the coated beads are crushed, and no detectable amount of naltrexone is released from the coated beads when tested intact, based on the dissolution at 1 hour in 900 ml of Simulated Gastric Fluid using a USP Type II (paddle) apparatus at 75 rpm at 37° C.63. The dosage form of claim 62 , wherein the amount of the opioid antagonist contained in the dosage form is sufficient to block the analgesic effect of the opioid agonist in a subject when the dosage form is chewed claim 62 , crushed claim 62 , heated or dissolved in a solvent claim 62 , and then administered orally.64. The dosage form of claim 63 , wherein the coating comprising the sequestering material separates the opioid antagonist from the opioid agonist.65. The dosage form of claim 63 , wherein the sequestering material comprises an ammonio methacrylate copolymer.66. The dosage form of claim 63 , comprising an additional coating comprising at least one pharmaceutically ...

Подробнее
Номер записи: 77
20-08-2015 дата публикации

ONCE-A-DAY OXYCODONE FORMULATIONS

Номер: US20150231131A1
Автор: OSHLACK Benjamin, Prater Derek, WRIGHT Curtis
Принадлежит:

The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C/Coxycodone ratio of 0.6 to 1.0 or 0.7 to 1 after oral administration at steady state to patients and methods thereof. 171-. (canceled)72. A sustained-release oral dosage form for once-a-day administration comprising:a plurality of units containing one or more active agents and one or more excipients, whereinone of the active agents is oxycodone or a pharmaceutically acceptable salt thereof, andthe excipients comprise a sustained release material comprising ethylcellulose, a methacrylic acid copolymer or a mixture thereof,wherein the amount of the oxycodone or pharmaceutically acceptable salt thereof in the dosage form is from about 10 to about 320 mg,{'sub': 24', 'max', 'max, 'the dosage form provides a mean C/Coxycodone ratio of from 0.6 to 1.0 and a mean Tof oxycodone of about 6.5 to about 17 hours after steady state oral administration to humans on a once-a-day basis, and'}the dosage form is a capsule.73. The dosage form of claim 72 , wherein the excipients are selected from the group consisting of (i) the sustained release material; (ii) cellulose ethers claim 72 , (iii) hydroxyalkylcellulose; (iv) plasticizers; (v) talc; and (vi) antioxidants.74. The dosage form of claim 72 , providing a mean C/Coxycodone ratio of about 0.7 to 0.99 after administration at steady state to said humans.75. The dosage form of claim 74 , providing a mean C/Coxycodone ratio of 0.7 to 0.95 after administration at steady state to said humans.76. The dosage form of claim 72 , providing a mean Tof oxycodone at about 8 to about 16 hours after administration at steady state to said humans.77. A sustained-release oral dosage form for once-a-day administration comprising a plurality of units comprising:oxycodone or a pharmaceutically acceptable salt thereof,a sustained release material comprising ethylcellulose, a methacrylic acid copolymer, a ...

Подробнее
Номер записи: 78
27-08-2015 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20150238481A1
Автор: Benjamin Oshlack, Christopher Breder, Curtis Wright
Принадлежит: PF Laboratories Inc, Purdue Pharmaceuticals LP

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Подробнее
Номер записи: 79
31-08-2017 дата публикации

Acetaminophen-Containing Analgesic Formulations With Reduced Hepatotoxicity

Номер: US20170246194A1
Автор: Curtis Wright, IV
Принадлежит: Purdue Pharma LP

An analgesic composition is provided which is safe and effective to patients requiring pain modulation. The analgesic composition contains (a) acetaminophen and (b) at least three components chosen from (i) a bioavailable oral opioid; (ii) a non-steroidal anti-inflammatory drug; (iii) a sulfur-containing, N-acetyl-p-benzoquinone imine scavenging agent or prodrug thereof; or (iv) an agent which lowers acetaminophen toxicity. These analgesic compositions inhibit the formation or reduce the presence of NAPQI, the toxic acetaminophen by-product responsible for liver toxicity in patients. These analgesic compositions are also safely tolerated by patients administering more than the maximum dosage of acetaminophen.

Подробнее
Номер записи: 80
24-09-2015 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20150265602A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A controlled release oral dosage form comprising:a mixture of (i) morphine or a pharmaceutically acceptable thereof; and(ii) a gelling agent comprising polyethylene oxide, the gelling agent in an effective amount to impart a viscosity unsuitable for parenteral administration when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid;the dosage form having a ratio of gelling agent to morphine or pharmaceutically acceptable salt thereof from about 40:1 to about 1:40;the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.42. The controlled release oral dosage form of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of at least about 10 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid.43. The controlled release oral dosage form of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of at least about 60 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid.44. The controlled release oral dosage form of claim 41 , wherein the gelling agent is in an effective amount to impart a ...

Подробнее
Номер записи: 81
24-09-2015 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20150265603A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A controlled release oral dosage form comprising:a mixture of (i) hydrocodone or a pharmaceutically acceptable thereof; and(ii) a gelling agent comprising polyethylene oxide, the gelling agent in an effective amount to impart a viscosity unsuitable for parenteral administration when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid;the dosage form having a ratio of gelling agent to hydrocodone or pharmaceutically acceptable salt thereof from about 40:1 to about 1:40;the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.42. The controlled release oral dosage form of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of at least about 10 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid.43. The controlled release oral dosage form of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of at least about 60 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid.44. The controlled release oral dosage form of claim 41 , wherein the gelling agent is in an effective amount to ...

Подробнее
Номер записи: 82
24-09-2015 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20150265604A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)42. The sustained release dosage form of claim 41 , providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.43. The sustained release oral dosage form of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of at least about 10 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid.44. The sustained release oral dosage form of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of at least about 60 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid.45. The sustained release oral dosage form of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity from about 120 cP to about 5 claim 41 ,000 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid.46. The sustained release oral dosage form of claim 41 , comprising from about 750 ng to about 750 mg of morphine or a pharmaceutically acceptable salt thereof.47. The sustained release oral dosage form of claim 41 , comprising from about 2.5 to about 800 mg of morphine or a pharmaceutically acceptable salt thereof.48. The ...

Подробнее
Номер записи: 83
24-09-2015 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20150265605A1
Автор: Benjamin Oshlack, Christopher Breder, Curtis Wright
Принадлежит: PF Laboratories Inc, Purdue Pharmaceuticals LP

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Подробнее
Номер записи: 84
24-09-2015 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20150265606A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A controlled release oral dosage form comprising:a mixture of (i) morphine or a pharmaceutically acceptable salt thereof; and(ii) a gelling agent comprising polyethylene oxide, the gelling agent in an effective amount to impart a viscosity unsuitable for parenteral administration when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid;a coating comprising a hydrophobic material, the coating applied on the matrix and comprising one or more passageways through the coating;the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.42. The controlled release oral dosage form of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of at least about 10 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid.43. The controlled release oral dosage form of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of at least about 60 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid.44. The controlled release oral dosage form of claim 41 , wherein the gelling agent is in an effective amount to ...

Подробнее
Номер записи: 85
24-09-2015 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20150265607A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A controlled release oral dosage form comprising:a mixture of (i) hydrocodone or a pharmaceutically acceptable salt thereof; and(ii) a gelling agent comprising polyethylene oxide, the gelling agent in an effective amount to impart a viscosity unsuitable for parenteral administration when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid;a coating comprising a hydrophobic material, the coating applied on the matrix and comprising one or more passageways through the coating;the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.42. The controlled release oral dosage form of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of at least about 10 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid.43. The controlled release oral dosage form of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of at least about 60 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid.44. The controlled release oral dosage form of claim 41 , wherein the gelling agent is in an effective amount to ...

Подробнее
Номер записи: 86
01-10-2015 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20150273064A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A controlled release oral dosage form comprising:a mixture of (i) from about 2.5 mg to about 320 mg of oxycodone or a pharmaceutically acceptable salt thereof; and(ii) a gelling agent comprising polyethylene oxide, the gelling agent in an effective amount to impart a viscosity unsuitable for parenteral administration when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid;a coating comprising a hydrophobic material, the coating applied on the matrix and comprising one or more passageways through the coating;the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.42. The controlled release oral dosage form of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of at least about 10 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid.43. The controlled release oral dosage form of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of at least about 60 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid.44. The controlled release oral dosage form of claim 41 , wherein the gelling ...

Подробнее
Номер записи: 87
01-10-2015 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20150273065A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A controlled release oral dosage form comprising:a mixture of (i) from about 2.5 mg to about 320 mg of oxycodone or a pharmaceutically acceptable salt thereof; and(ii) a gelling agent comprising polyethylene oxide, the gelling agent in an effective amount to impart a viscosity unsuitable for parenteral administration when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid;a coating comprising an aminoalkyl methacrylate copolymer;the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.42. The controlled release oral dosage form of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of at least about 10 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid.43. The controlled release oral dosage form of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of at least about 60 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid.44. The controlled release oral dosage form of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of at least about 120 cP ...

Подробнее
Номер записи: 88
04-12-2014 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20140357657A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A controlled release oral dosage form comprising:a mixture of (i) from about 2.5 mg to about 320 mg oxycodone or a pharmaceutically acceptable salt thereof; and(ii) a gelling agent comprising polyethylene oxide and hydroxypropylmethylcellulose, the gelling agent in an effective amount to impart a viscosity of at least about 10 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid;the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.42. The controlled release oral dosage form of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of at least about 60 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid.43. The controlled release oral dosage form of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of at least about 120 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid.44. The controlled release oral dosage form of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of at least about 375 cP when the dosage form is subjected to ...

Подробнее
Номер записи: 89
08-10-2015 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20150283128A1
Автор: Benjamin Oshlack, Christopher Breder, Curtis Wright
Принадлежит: PF Laboratories Inc, Purdue Pharmaceuticals LP

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Подробнее
Номер записи: 90
08-10-2015 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20150283129A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)42. The sustained release dosage form of claim 41 , providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.43. The sustained release oral dosage form of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of at least about 10 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid.44. The sustained release oral dosage form of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of at least about 60 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid.45. The sustained release oral dosage form of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity from about 120 cP to about 5 claim 41 ,000 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid.46. The sustained release oral dosage form of claim 41 , comprising from about 10 mg to about 160 mg oxycodone hydrochloride claim 41 , the dosage form providing a mean minimum plasma concentration of oxycodone from about 3 to about 120 ng/ml from about 10 to about 14 hours after administration every 12 hours after repeated ...

Подробнее
Номер записи: 91
08-10-2015 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20150283130A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A controlled release oral dosage form comprising:a mixture of (i) from about 10 mg to about 160 mg oxycodone or a pharmaceutically acceptable salt thereof; and(ii) a gelling agent in an effective amount to impart a viscosity unsuitable for parenteral administration when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid;the dosage form having a ratio of gelling agent to oxycodone or pharmaceutically acceptable salt thereof from about 40:1 to about 1:40;the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient and providing a mean minimum plasma concentration of oxycodone from about 3 to about 120 ng/ml from about 10 to about 14 hours after administration every 12 hours after repeated dosing through steady state conditions and providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.42. The controlled release oral dosage form of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of at least about 10 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid.43. The controlled release oral dosage form of claim 41 , wherein the gelling ...

Подробнее
Номер записи: 92
08-10-2015 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20150283250A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A controlled release oral dosage form comprising:a mixture of (i) from about 2.5 mg to about 320 mg oxycodone or a pharmaceutically acceptable salt thereof; and(ii) a gelling agent selected from the group consisting of polyethylene oxide, a cellulosic polymer and a combination thereof, the gelling agent in an effective amount to impart a viscosity unsuitable for parenteral administration when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid;the dosage form having a ratio of gelling agent to oxycodone or pharmaceutically acceptable salt thereof from about 40:1 to about 1:40;the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.42. The controlled release oral dosage form of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of at least about 10 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid.43. The controlled release oral dosage form of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of at least about 60 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid.44. The ...

Подробнее
Номер записи: 93
18-12-2014 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20140371257A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A controlled release oral dosage form comprising:a mixture of (i) from about 10 mg to about 160 mg oxycodone or a pharmaceutically acceptable salt thereof; and(ii) a gelling agent in an effective amount to impart a viscosity of at least about 10 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid;the dosage form providing a mean minimum plasma concentration of oxycodone from about 3 to about 120 ng/ml from about 10 to about 14 hours after administration every 12 hours after repeated dosing through steady state conditions and providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.42. The controlled release oral dosage form of claim 41 , providing a mean maximum plasma concentration of oxycodone from about 6 to about 240 ng/ml from a mean of about 2 to about 4.5 hours after administration.43. The controlled release oral dosage form of claim 41 , comprising (i) from about 10 to about 40 mg oxycodone hydrochloride claim 41 , the dosage form providing a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng/ml from a mean of about 2 to about 4.5 hours after administration or (ii) from about 40 mg to about 160 mg oxycodone hydrochloride claim 41 , the dosage form ...

Подробнее
Номер записи: 94
19-10-2017 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20170296533A1
Автор: Benjamin Oshlack, Christopher Breder, Curtis Wright
Принадлежит: PF Laboratories Inc, Purdue Pharmaceuticals LP

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Подробнее
Номер записи: 95
08-10-2020 дата публикации

INSTRUMENT PANEL WITH REINFORCEMENT MEMBER

Номер: US20200317275A1
Автор: Thomas Louis, Vitale Peter, WRIGHT Curtis
Принадлежит:

A method and apparatus includes a substrate, a foam that is applied to the substrate to form a least a portion of an interior trim part, at least one holder fixed to the substrate, and at least one reinforcement member supported by the at least one holder such that, when the foam is applied, the at least one reinforcement member is suspended within the foam. 1. An apparatus comprising:a substrate:a foam that is applied to the substrate to form a least a portion of an interior trim part;at least one holder fixed to the substrate; andat least one reinforcement member supported by the at least one holder such that, when the foam is applied, the at least one reinforcement member is suspended within the foam.2. The apparatus according to claim 1 , wherein the at least one reinforcement member comprises at least one tube.3. The apparatus according to claim 2 , wherein the at least one tube includes a hollow center through which gas vents when the foam is applied to the substrate.4. The apparatus according to claim 2 , wherein the at least one tube is positioned within the foam to extend along a brow of the interior trim part.5. The apparatus according to claim 1 , wherein the at least one reinforcement member comprises a plurality of wires and/or tubes.6. The apparatus according to claim 1 , wherein the at least one holder comprises at least one clip.7. The apparatus according to claim 6 , wherein the at least one clip includes a connector end that is fixed to the substrate and a grip end that receives the at least one reinforcement member.8. The apparatus according to claim 1 , including a skin that covers the foam to form an exterior surface of the interior trim part claim 1 , and wherein the at least one reinforcement member is spaced apart from the skin and the substrate once suspended in the foam.10. The interior trim part according to claim 9 , wherein the at least one reinforcement member comprises at least one tube that includes a hollow center through which gas ...

Подробнее
Номер записи: 96
30-11-2017 дата публикации

OXYCODONE FORMULATIONS

Номер: US20170340626A1
Автор: OSHLACK Benjamin, Prater Derek, WRIGHT Curtis
Принадлежит:

The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C/Coxycodone ratio of 0.6 to 1.0 or 0.7 to 1 after oral administration at steady state to patients and methods thereof 171-. (canceled)72. A sustained release oral dosage form comprisinga core comprising oxycodone or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable polymer,a membrane surrounding the core, anda passageway in the membrane,{'sub': 24', 'max, 'the dosage form providing a mean C/Coxycodone ratio of from 0.6 to 1.0 after steady state oral administration with food to humans.'}73. The dosage form of claim 72 , wherein the core is substantially homogeneous.74. The dosage form of claim 72 , wherein the pharmaceutically acceptable polymer is a polyalkylene oxide.75. The dosage form of claim 74 , wherein the polyalkylene oxide is a polyethylene oxide.76. The dosage form of claim 72 , wherein the membrane is a semipermeable membrane.77. The dosage form of claim 72 , which provides a mean C/Coxycodone ratio of from 0.7 to 0.99 after said administration.78. The dosage form of claim 72 , which provides a mean C/Coxycodone ratio of from 0.8 to 0.95 after said administration.79. The dosage form of claim 72 , which provides a mean C/Coxycodone ratio of from 0.7 to 1.0 and a mean Tof oxycodone in about 2 to about 17 hours after said administration.80. The dosage form of claim 72 , which provides a mean C/Coxycodone ratio of from 0.72 to 0.99 and a mean Tof oxycodone in about 2 to about 17 hours after said administration.81. The dosage form of claim 72 , which provides a mean C/Coxycodone ratio of from 0.74 to 0.95 and a mean Tof oxycodone in about 2 to about 17 hours after said administration.82. The dosage form of claim 72 , which provides a mean Tof oxycodone in about 8 to about 16 hours after said administration.83. The dosage form of claim 72 , which provides a mean Tof oxycodone in about 10 ...

Подробнее
Номер записи: 97
31-12-2015 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20150374628A1
Автор: Benjamin Oshlack, Christopher Breder, Curtis Wright
Принадлежит: PF Laboratories Inc, Purdue Pharma LP, Purdue Pharmaceuticals LP

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Подробнее
Номер записи: 98
31-12-2015 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20150374631A1
Автор: Breder Christopher, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A controlled release oral dosage form comprising:a matrix comprising (i) an opioid agonist; and(ii) a gelling agent selected from the group consisting of polyethylene oxide, a cellulosic polymer and a combination thereof, the gelling agent in an effective amount to impart a viscosity unsuitable for parenteral administration when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid;the dosage form having a ratio of gelling agent to opioid agonist from about 40:1 to about 1:40;the matrix providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.42. The controlled release oral dosage form of claim 41 , wherein the cellulosic polymer is hydroxypropylmethylcellulose.43. The controlled release oral dosage form of claim 42 , wherein the gelling agent comprises polyethylene oxide and hydroxypropylmethylcellulose.44. The controlled release dosage form of claim 43 , wherein the gelling agent further comprises polyethylene glycol.45. The controlled release dosage form of claim 44 , further comprising alpha-tocopherol.46. The controlled release dosage form of claim 44 , wherein the matrix is a compressed tablet.47. The controlled release dosage form of claim 46 , wherein the tablet is coated with a film ...

Подробнее
Номер записи: 99
21-11-2019 дата публикации

TAMPER RESISTANT ORAL OPIOID AGONIST FORMULATIONS

Номер: US20190350868A1
Автор: HADDOX J. David, OSHLACK Benjamin, WRIGHT Curtis
Принадлежит:

Oral dosage forms containing an opioid antagonist in a sequestered form are described. The opioid antagonist is sequestered such that it is not released or substantially not released in the gastrointestinal tract from the dosage form which is administered orally intact. However, when the dosage form is chewed, crushed, heated or dissolved in a solvent, and then administered orally, intranasally, parenterally or sublingually, the opioid antagonist is released and at least partially blocks effects of the opioid agonist. 161-. (canceled)62: An oral dosage form comprising:an opioid agonist, andmultiparticulates comprising an opioid antagonist and a sequestering material, the sequestering material separating the opioid antagonist from the opioid agonist,wherein the multiparticulates are dispersed in a matrix comprising the opioid agonist, and the opioid antagonist is substantially not releasable from the dosage form which is administered orally intact such that the dosage form releases not more than 12.5% of the opioid antagonist at 1 hour when administered orally intact, andthe opioid antagonist is naltrexone hydrochloride.63: The dosage form of claim 62 , wherein the dosage form is a compressed tablet.64: The dosage form of claim 62 , wherein the opioid agonist is selected from the group consisting of hydrocodone claim 62 , hydromorphone claim 62 , morphine claim 62 , oxycodone claim 62 , oxymorphone claim 62 , and pharmaceutically acceptable salts thereof.65: The dosage form of claim 62 , wherein the sequestering material comprises an ammonio methacrylate copolymer.66: The dosage form of claim 62 , wherein the dosage form comprises oxycodone or a pharmaceutically acceptable salt thereof.67: The dosage form of claim 66 , which comprises 10 mg claim 66 , 20 mg claim 66 , 40 mg claim 66 , or 80 mg oxycodone hydrochloride.68: The dosage form of claim 62 , which comprises from about 10 ng to 275 mg naltrexone.69: The dosage form of claim 68 , which comprises from 0.4 mg to ...

Подробнее
Номер записи: 100
26-12-2019 дата публикации

Ultrafast, multiphoton-pump, multiphoton-probe spectroscopy

Номер: US20190391070A1
Автор: Daniel David Kohler, Darien James Morrow, John Curtis Wright
Принадлежит: WISCONSIN ALUMNI RESEARCH FOUNDATION

Methods for pump-probe spectroscopy are provided. In an embodiment, such a method comprises directing pump light having a frequency ω pump at a location in a sample to excite a transition between two quantum states of a target entity in the sample, directing probe light at the location to generate a coherent output signal having a frequency ω output and a wavevector k output , and detecting the output signal as the probe light is scanned over a range of frequencies. In the method, either the transition excited by the pump light is a multiphoton transition corresponding to a frequency difference of n*ω pump , wherein n≥2; or the probe light is a set of m coherent light pulses, each coherent light pulse having a frequency ω m and a wavevector k m , wherein m≥2; or both. Systems for carrying out the methods are also provided.

Подробнее
Номер записи: 101